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Abstract
Mergers and acquisitions in the Medical Device Industry are the primary mode of exit for early
stage companies. The focus of this thesis is to examine factors which influence the value of these
M&A transactions from the target and acquiring firm perspectives and to understand the value
creation that occurs. Publicly available electronic and published data sources were used to build a
database of 674 M&A transactions and 113 IPO events for deals with published deal values and
terms between January 1996 and October 2006. In this work, we demonstrate that transaction deal
value varies between various medical device industry sectors. Factors that were shown to
significantly correlate with M&A transaction deal value included the Sales of the target company,
Market Capitalization value of the acquiring company, type of regulatory approval, and whether
the company had venture backing prior to acquisition. M&A transactions that involved targets that
were Public companies had significantly higher deal values than those that were private. Using 3-
day event window analysis, returns of acquiring companies were shown to be slightly negative and
significantly less than the S&P composite index returns over the same period. Previous studies
suggest that managers in larger firms tend to use overvalued stock and empire building behavior,
resulting in overbidding or pay more for acquisitions. No significant difference in deal value was
associated with financing terms between cash and stock transactions. The use of earn outs had no
effect on the deal value or the acquirer stock returns. Markets that are developing will continue to
have increasing deal value as firms attempt to establish market share and or acquire breakthrough
technologies. We found that there were positive correlation of M&A or IPO transaction value for
companies in less mature markets where companies have opportunities to leap frog other
companies in market position and share. Conversely, there is negative correlation of M&A or IPO
transaction value for companies in more mature markets. The results are discussed in terms of the
specific factors that influence the transaction value and the degree to which target and acquiring
firms benefit from M&A transactions.
Thesis Supervisor: Anthony Sinskey, Sc.D.
Title: Professor of Microbiology and Health Sciences and Technology
Thesis Supervisor: Antoinette Schoar, Ph.D.
Title: Michael M. Koerner Associate Professor of Entrepreneurial Finance
To my parents,
Masayuki and Bessie Ohashi
Acknowledgements
Over the past three years I have had the pleasure to work with and be mentored by an outstanding
group of individuals at MIT, Harvard, HMS, and MGH through the Biomedical Enterprise
Program. The experiences and insights that the individuals associated with the program have
shared with me has helped me grow as a student, professional, and entrepreneur - to this I am
greatly indebted to the faculty, staff and students involved with the program.
I would like to extend my gratitude and appreciation to Prof. Anthony Sinskey for his advice,
guidance, and assistance over the past three years. In addition, I would like to thank Prof. Sinskey
and Prof. Antoinette Schoar for serving as my thesis advisors. I would like to express my
appreciation to Profs. Martha Gray and Edward Roberts for serving as my HST and MIT Sloan
academic advisors.
My experiences while in the Biomedical Enterprise Program would not have been complete
without the faculty, staff and fellow students at MIT, HMS, and MGH. I would like to give a
special thank you to Marsha Warren, Bonnie Fendrock, Prof. James Utterback, David Weber, Traci
Anderson, Dr. Rox Anderson, Dr. Steven Zeitels, Prof. Ernie Berndt, and Prof. Richard Cohen. To
my fellow BEPers to whom I have tremendous respect and admiration, I have been inspired by
your entrepreneurial spirit and passion. I look forward to spending many more years working and
learning from all of you as both a colleague and friend.
Alas, I would like express a deep appreciation and thank you to Elise Morgan for her undying
support, love, and understanding over the past three years as I have juggled the many different
aspects of student, professional, and personal life challenges.
Table of Contents
A bstract ................................ ............................................................................................................................. 2
Acknowledgements ........................................................................................................................................... 4
Table of Contents ................................................................................................................................ 5
List of Figures ................................................................................................................................................... 7
List of Tables ............................................................................................................................................. 8
Chapter 1: Introduction .................................................. 10
Mergers and Acquisitions ...................................... 10
How are target firms valued? .. .. .. .. . .. .. .. .. .. .. .. .. .. .. .. . . ......... 11
Financing Method [1-31] .................................................. 11
Other financing options ................................................. 12
Who benefits from the merger or acquisition? ......................................................... . .. ... . . . . . . .. .. ......... 12
Overall Aim of Thesis .................................................. 13
Overall Hypothesis ............................................ ......... 14
Significance of Hypotheses ........................................................................................................................ 16
Chapter 2: Medical Device Industry ..................................................................................................... 17
General Statistics.................................................................................................. 17
M ergers and A cquisition ................................................................................................................ 18
Value creation in the Medical Device Industry ........................................................ 22
Medical Device Industry Regulation - Food and Drug Administration (FDA) [12] ......................... 23
United States Regulation of Medical Device Products .................................................................... 24
Premarket Notification 510(k) ............................................ 25
Premarket Approval (PMA) .............................................................................................................. 25
Investigational Device Exemption (IDE) .............................................................. ......................... 26
FD A clearance tim es ........................................ ... ............. ............................................................. 26
Other factors in the Medical Device Industry ............................... ............................. 28
Exit Potential for Medical Device Companies ...................................................... .................... 30
Consolidation of major players ........................................ .............................................. 31
Concerns about consolidation? ..... . . . . . .. . . .. .. . . ......... .. .. . .. .. .. .. .. .. .. .. .. .. . . . . 32
Advantages of consolidation ........ .................................................... 32
Profile of medical device companies that are prime for acquisition [2] .................................... .... 33
What are acquirers looking for? [1, 2] ............................................................. ............................ 33
Summary....................... .... ................................................................. 33
Chapter 3: Methods ............................................................................................................................. 35
Summary: .................................................................. 
.................................. 35
Transaction Database .................................................................................................................. 35
E lectronic D atabases ................................................................................................... ......................... 36
Published Journal Source ................................................................................. .................................. 37
United States FDA Regulatory Databases [12, 19] .................................... 37
Information Collected and Terms Used in the Analysis .................................. 37
D escriptive Statistics .......................................................... ...................................................................... 39
Multivariate Linear regression model..................................................................... ......................... 39
Chronology of Deal within an Industry Sector ............................................... .................... 40
Chapter 4: Results ......................................................................................................................................... 41
Medical Device Industry Database Summary: ......................................................... 41
M&A Deal value Distribution ........................... .............................................. ............................. 41
A verage Size of A cquirer............................................................................................. ....................... 42
Target Company Sales .............................. .. ... ...... ............ ................... 42
Medical Device Industry Transactions and Mean Deal Value ..................................... .......... 48
A cquirer Size........................................................................................ .............................................. 53
A cquirer D iversification.............................................................................. ....................................... 57
Internal factors ........................................................................................................................................ 58
Influence of Venture Capital Financing ............................................................................................. 58
R egulatory A pproval....................................... ........................... ................................................ 60
Sales and R evenue: .................................................................................. .......................................... 63
T ransaction Financing ................................... ................. ............................. ................................ 64
Earn outs and R eturns ....................................... ............................................................................... 65
Chronological Order of Acquisition - Example Cases .................................................... 67
Chapter 5: Summary .............................................................................................................................. 76
Appendix ......................................................................................................................................................... 86
6
List of Figures
Figure 1: Research and Development (R&D) spending in the Medical Device Industry from 1990-2002 for
publicly traded companies as a percentage of sales [8]. ...................................................... 17
Figure 2: Globally announced Mergers and Acquisitions Medical Device Transactions between 1996 and
2001 [10] ................................ . ............ ... .......... ....... ......................... 20
Figure 3: Graphical representation of a Medical Device Company life cycle. ............................................... 23
Figure 4: United States FDA Regulatory Approval times for (a) 510(k) Clearance and (b) PMA Approval
T im e [13] ............................................. ............. ..... ........................ ............................... 27
Figure 5: Medical device patents from 1989 to 2003 [8] ................................................................ 30
Figure 6: Number of Medical Device M&A transactions as a function of year..................................41
Figure 7: Graphical representation of (a) Histogram of the Medical Device deal values for companies less
than $250MM showing asymmetric distribution in deal values, (b) Log transformation of all
deal values to obtain a normal distribution for the linear regression model. ........................... 43
Figure 8: Graphical representation of (a) Histogram of the acquirer sales values for companies with less than
$1B showing asymmetric distribution of acquirer sales, (b) Log transformation of the acquirer
sales for all companies to obtain a normal distribution for the linear regression model.............44
Figure 9: Graphical representation of (a) Histogram of the acquirer market capitalization for companies less
than $2B showing asymmetric distribution in market capitalization of acquirers, (b) Log
transformation of the market capitalization values to obtain a near normal distribution for the
linear regression m odel ................................................................................................ 45
Figure 10: Graphical representation of (a) Histogram of the target companies reporting actual sales numbers
for companies less than $250MM in sales showing asymmetric distribution of sales, (b) Log
transformation of the sales values to obtain a near normal distribution for the linear regression
model ............... ..................... .... ............................................................ . 46
Figure 11: Graphical representation of (a) Number of Medical Device Industry IPO transactions and mean
amount of money raised as a function of year and (b) Comparison between the number of
Medical Device Industry IPO and M&A transactions as a function of year............................52
Figure 12: The number of Medical Device M&A transactions that venture and non-venture backed
companies as (a) a function of year and (b) mean deal value ..................................... .... 61
Figure 13: Medical Device Industry deal value as a function of type of regulatory approval ..................... 62
Figure 14: Graphical representation of Log(Deal Value) Actual values plotted against Log(Deal Value)
Predicted values... ........................................................................................................... 67
Figure 15: Graphical representation of linear regression of Log(Deal Value) versus order of transaction for
(a) Cardiovascular Devices, (b) Vascular Devices, (c) Orthopaedic Devices and Equipment, and
(d) Neurology Devices....... ......................... ........................................................ 75
List of Tables
Table I: Research and Development (R&D) Spending as a Percentage of Sales in 2002 for Specific Industry
Sectors ................. .................................... .............................................................. 18
Table II: Leading medical device companies ........................................ ...... .... .................................. 21
Table III: Industry Sectors in the Medical Device Industry ...................................................................... 21
Table IV: Number of Medical Device Industry Transactions and Mean Deal Value as a Function of Year ...48
Table V: Mean Deal Values for the Various Medical Device Industry Sectors................................. 49
Table VI: Deal value as a function of the Medical Device Industry sectors. The OLS Regression model uses
Log (Deal Value) as the dependent value and Date (Year) and Industry Sector as the
independent values. Women's Health sector is the base comparison sector in the model.........50
Table VII: Mean Deal Value as a function of Year for firms that IPOed versus NO IPO prior to M&A
transaction .......................................................................................................................... 53
Table VIII: Size of Acquiring companies and the Associated Mean Deal Values of the Companies.............54
Table IX: Deal value as a function of the Acquirer Characteristics. The OLS Regression model uses Log
(Deal Value) as the dependent value and Date (Year), Acquirer Market Cap and Acquirer Sales.
.......................................... ....................... ........ .............. ................ .................. . . . .. 55
Table X: Deal value as a function of the Acquirer Characteristics and 30 Day returns. The OLS Regression
model uses Log (Deal Value) as the dependent value and Date (Year), Acquirer Market Cap
and 30 day returns.................................... ........................................................................... 55
Table XI: Top 25 Companies Based on Number of Acquisitions Between 1996 and 2006* ...................... 58
Table XII: Venture Financing from January 1996 to October 2006 for Selected Medical Diagnostic,
Therapeutic, and Medical/Health Product Companies. ...................................... ...... 59
Table XIII: Medical Device Industry M&A transaction with Multiple Regulatory Approvals and the
associated M ean Deal Values .................. ..................... ................................................. 63
Table XIV: Type of Regulatory Approval for the different Medical Device Industry Sectors ................... 63
Table XV: Deal value as a function of the Medical Device Industry sectors and Target Sales. The OLS
Regression model uses Log (Deal Value) as the dependent value and Date (Year), Industry
Sector, and Target Sales prior to acquisition as the independent values. Women's Health sector
is the base comparison sector in the model...................................................64
Table XVI: Medical Device Deal Financing Type and the Associated Mean Deal Values......................... 65
Table XVII: Deal value as a function of multiple factors. The OLS Regression model uses Log (Deal Value)
as the dependent value and Date (Year), Earn outs, Log(Target Sales), Log(Acquirer Sales),
Log (Acquirer Market Cap), Regulatory approval, Multiple regulatory approvals, Financing
(cash, stock, debt), Venture backing, and target public or private as the independent values....66
Table XVIII: Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Cardiovascular Device-Atrial Fibrillation Company Example ........................ 69
Table XIX: Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Vascular Devices-Femoral Closure Company Example .................................. 70
Table XX: Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Neurology Devices - Neurostimulation Company Example ........................... 72
Table XXI:Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Orthopaedic Devices - Spine Technology Company Example ....................... 74
Table XXII: M &A Transaction Deal Value Data ........................................ ............................................ 86
Chapter 1: Introduction
Mergers and Acquisitions
The dynamic consolidation of firms in the Medical Device Industry occurs by active merger and
acquisition (M&A) behavior by larger firms attempting to increase efficiencies, drive growth,
and/or diversify holdings. This active M&A environment is driven by the globalization of the
economy and increase in the global competition in the Medical Device Industry. Acquisition of
target firms enables acquirers to enter new markets (product or geographical base), expand product
offerings to be competitive in established markets (product pipelines), optimize and add to existing
sales and distribution channels (vertical integration), utilize/take advantage of manufacturing
capabilities through both economies of scale and scope, add new technologies and capabilities to
the firm, and potentially establish market position in new markets. As a result, underlying benefits
to the acquirer include opportunities to increase or capture market share in competitive markets, re-
supply the product pipelines and reinvigorate the sales forces. Additional benefits include enabling
acquirers the power to not only diversify product offerings but bundle product offerings and
therefore provide the firm more leverage with large group purchasing organizations (i.e. HMOs and
health care companies) and therefore potentially better product purchasing terms. Through
economies of scale the acquirers can optimize administration, sales and distribution,
manufacturing, and management resources. Acquisitions will potentially allow the acquirer to
more efficiently utilize complementary resources that include technologies, manufacturing
capabilities, sales and engineering talent, and management capabilities. However less compelling
is the use of M&A to diversify holdings. Specifically, it is questionable if diversification increases
value of the company. The rationale is that markets are efficient and generally investors have their
own opportunity to diversify assets so this is not necessarily value adding for firms to diversify
assets.
Problems with M&A that may not add to shareholder value include diversification of assets,
manager hubris (manager's overpay for targets because of their over confidence in synergies
between the firms), and empire building by managers. Internal problems associated M&A
transactions have included integration of target and acquiring firm assets, resources and people
including compatibility issues (i.e. technology, culture) and redundant resources (i.e. staff,
manufacturing, R&D and sales people and resources). A consequence of M&A transactions can be
loss of people and therefore loss in expertise, management and disruption in employee culture. The
end result of failed M&A integration is loss in shareholder value. Accordingly, the deals
associated with M&A in the Medical Device Industry in part may take into account these M&A
challenges through deal value and deal terms. Reducing risk in M&A transactions include better
due diligence on the financial and operational components of the target and potential liabilities or
other major issues that can have direct impacts on the acquirer. Success or failure of integration of
a target firm may be reflected by both the short and long term returns observed by the acquiring
firm.
How are target firms valued?
Generally the valuation of a company can be computed by discounted cash flow based on the
present value of future streams of cash flow based on discounting the future cash flows expected
several years in the future using a discount rate. Note the discount rate is the rate that future cash
flows are discounted based on the time value of money. This method of valuation works well for
firms with established revenue streams. However, firms that are early in the life cycle of their
product or technology, this method of market projection may be less attractive. Alternatively, the
value of the firm can be determined by a multiple of the current revenue, cash flow, net worth, or
operating assets.
Financina Method 11-31
Acquirers will tend to use equity as payment, particularly if it is overvalued. The downside of
using equity is that it may signal to the market that the managers of the acquirer believe that the
stock is overvalued. Moreover, equity based transactions usually take longer to execute. Target
companies generally want guaranteed cash instead of stock. The payment type has tax implications
- acquisitions can be taxed or be tax-free. If the acquisition is financed with cash, the acquisition is
taxable because the target shareholders are essentially selling their shares. As a result of this
transaction, the target shareholders will have to pay a capital gains tax on the proceeds. However,
if the transaction involves share exchange, the transaction is tax free. Transactions involving
shares is considered a swapping of shares for shares with no capital gains recognized. This also
has implications on the acquiring firm. If the transaction is tax-free, the resulting tax status of the
combined firm is as if both firms were always one firm. In the instance where the transaction is
taxable, the assets of the target firm can be treated as a gain or loss (write up or write down) and
depreciated on recalculation of the assets. Cash based acquisitions reduces the complexity of
acquisition in terms of negotiations and valuation. Smaller firms more frequently tend to use cash
[4]. The downside of a cash acquisition for the acquirer is that it takes away working capital.
Stock based transactions are generally better for the acquirer (cheaper) because the value of the
shares is generally higher than the book values as compared to paying cash. Moreover, stock based
transactions saves working capital and as discussed above are tax free transactions. Additional
upside (short term) with stock transactions is the instant increase in earnings of the acquiring firm
(assuming that the target firm has earnings) for the year of acquisition. The result is the acquisition
will lead to higher earnings per share for the acquirer! According the payment type can have an
impact on the value of the deal. Moeller et al. 2004 demonstrated that larger firms that used equity
as the financing payment tended to have negative abnormal returns. This was compared to
significant positive abnormal returns for smaller firms that used either cash or equity financing
terms.
Other financing options
An alternative to M&A is an Initial Public Offering (IPO). IPOs are a sale of share in a company
to the public that is regulated by the Security and Exchange Commission (SEC). Stocks are
available to the public markets in the United States through the NYSE, AMES, or NASDAQ stock
exchanges. Primary reasons to pursue an IPO for a target firm are to access capital from the public
markets (used for expansion (sales), funding of clinical studies, acquisition strategies, etc...) and/or
liquidity for shareholders. Once firms have issued their IPO they have a much larger public
presence and begin to build brand recognition on a different level. Challenges for target firms that
enter the public markets are management of the cost, effort, disclosures, and pressures associated
with being a company that has shares available on the public markets.
Who benefits from the merger or acquisition?
The acquiring firm will identify key individuals that they will need to stay in with the Target firm
for the acquisition to be successful, identify key relationships that need to be maintained (i.e.
surgeons, distributors, sales, scientists, etc...), and develop a strategy for integration of the Target
firm into the Acquiring firm (culture, operations, etc...). Generally, key individuals at the target
firm will generally stay for a short transition period. However, it is typically a difficult cultural
change for the target firm employees. Finally, there exists much uncertainty among key
relationships that were built on trust and respect (i.e. surgeons, customers, sales and distribution
channels, etc...). The integration of the two firms is generally quite difficult.
Target or acquired firm benefit immediately from acquisition by being able to access larger markets
through the resources of the acquiring firm (i.e. sales and marketing, manufacturing, etc...) and
having access to financial resources that may be required to demonstrate clinical proof of benefit or
to commercialize new products. However, the target firms seem to benefit immediately from the
transaction, whereas acquiring firms are expected to generally break even from the transaction
(based on historical returns). Another factor which may help target firms benefit is the presence of
multiple bidders in the transaction that are vying for the company. The multiple bids can lead to
better terms and lead to premium pricing for the target firm. An example of this type of behavior
was observed with the $27B Guidant acquisition battle between J&J and Boston Scientific in 2005.
Overall Aim of Thesis
The resources that the acquirer provides to the target firm therefore not only benefit the target firm
but generally leads to increase value of the acquiring firm by accelerating the value contribution of
the acquired firm. Historically, using 3 day event windows (in terms of stock returns) in M&A
transactions, the acquirer usually does not see gains (minor insignificant losses, -0.7%), whereas
target firms usually have larger returns (16%) leading to a net combined effect showing increased
value for the firms. Taking a longer event window of 20 days (in terms of stock returns) the
acquirer generally continues to lose (still relatively insignificant, -3.8%) and the Target usually
continues to gain (23.8%) [5]. It appears that target firms come out ahead in M&A transactions in
most instances. One can estimate the value that the target firm extracts from these transactions by
using deal value and the terms of the merger and acquisition as proxies. Whereas, in order to
determine the value that the acquiring firm extracts one may use stock market returns over a
specified event period that includes time before and after the acquisition of the target firm. Closer
examination of internal company factors (i.e. whether a company has revenues, regulatory
approval, venture funded, chronology of deal) and external industry factors (i.e. industry sector,
revenue of acquirer, comparables, access to IPO market, market cap of acquirer, market maturity)
can provide a better understanding of how these factors influence deal terms directly or indirectly.
To date, a framework to explain where value is created and captured by target and acquiring firms
through merger and acquisition transactions has not been developed. Accordingly, the overall aim
of this thesis is to determine the effect that specific internal and external value factors have on the
merger and acquisition terms (i.e. earn out terms, payment type), deal values, and stock market
returns in the medical device industry between the period of January 1996 through October 2006.
Overall Hypothesis
The overall hypothesis of this work is that specific internal and external factors will significantly
affect the deal terms and value of the merger and acquisition and the values extracted by the target
and acquiring firms can be correlated to these factors using statistical analysis of the deal value and
terms. The basis of the specific internal and external factors analyzed is described in the Medical
Device Industry Overview in Chapter 2. The following hypotheses will be the basis of the analysis
performed in this thesis:
1. The medical industry is unlike most other industries in that it is highly regulated by the
Food and Drug Administration (FDA) for approval to sell product and the Centers for
Medicare and Medicaid Services for reimbursement of the product or service.
Accordingly, key internal milestones for companies in the medical device industry include
FDA approval to market and sell a product and product sales (which is usually driven by
reimbursement in most instances) as a demonstration of the market potential. Companies
that are able to achieve these milestones create value and significantly impact the target
acquisition value. In addition, other internal factors involving financing sources (i.e.
venture funding) can indicate ability to execute and management strength of the target
firm. External factors such as industry sector, acquirer sales, acquirer market
capitalization, comparable deals, and access to the public markets can also be factors in
determining exit values. Accordingly, it is hypothesized that Merger and Acquisition deal
value in the medical device industry is significantly higher for target firms that have
achieved regulatory and sales milestones and that have venture funding. Moreover, that
these acquirer characteristics and sector trends will affects the target company valuations
and therefore deal value.
2. Value for target and acquiring companies can be measured by examining the value created
for the target firm shareholders and the value created for the acquiring firm shareholders.
Generally the target firm shareholders capture value with the acquisition payout and value
creation can be measured by the deal value. However, the value capture by the acquiring
firm is less clear cut. In fact, it is generally thought that acquiring firm shareholders
essentially break even on the transaction or even lose and essentially finance the
transaction. Accordingly, acquiring firms use a variety of deal terms or financing terms to
affect the value of the deal transaction. For example, it has been hypothesized that firms
that have overvalued stock tend to pay more for target firms [4]. In addition, acquiring
firms use of stock, debt, and cash and its influence on the deal value and terms of the
acquisition. It is hypothesized that transactions that use stock in the financing will have
higher deal value as compared to those that are based on cash financings. Three-day and
three hundred and sixty day event windows will be examined to gain insight into the value
created for the acquiring company by acquisition of the target firm.
3. Increasingly it appears that acquirers utilize earn out or milestone based terms in deals to
address market and regulatory risks and/or maintain target company employee incentives
post-acquisition. Alternatively, this may also be a mechanism for target firms to extract
more value in the transaction if it deems itself as being undervalued by the acquiring firm.
Regardless, it is hypothesized that reported deal value is lower for merger and acquisition
deals that include earn out or milestone payments in the deal terms. Note: deal terms
based on earn out or milestone payments schedules are generally not available to the
public. We believe that the presence of earn out or milestone terms in the deal may provide
a signal to the market that the target firm is a relatively risky acquisition. As a result, it is
also hypothesized that the relative risk of the acquisition should be reflected by lower
acquirer stock price performance as compared to deals that do not contain earn out or
milestone terms. The value extracted through earn out use is therefore shared by both the
target and acquiring firms.
4. Entering new markets has inherent risks associated with unknown revenue potential due to
a variety of factors (i.e. immature markets, regulatory or reimbursement issues). However,
once markets develop, target companies with large market share may experience larger
merger and acquisition deal values as compared to target companies that follow.
Additionally, first mover advantage and demonstration of clinical benefit are strong ways
to establish market share. However, the innovation and rapid changes in the Medical
Device Industry can result in rapid uptake and valuation of technologies. It is hypothesized
that deal values will be significantly lower in increasing chronological order of either
acquisition or IPO exit of the target company in mature markets. However, in markets that
are developing (i.e. strong market leader is not present because clinical benefit is not
established or an effective therapeutic device that has not emerged) will continue to have
increasing deal value as firms attempt to establish market share and or acquire the
breakthrough technology.
Si2nificance of Hypotheses
Determining the contributions of various target and acquirer characteristics on deal value is very
complex. In this work we attempt to develop a better understanding of how various internal and
external factors correlate with the final deal terms and value of the transactions. The first
hypothesis provides a basic analysis of how key internal milestones and external characteristics of
the acquirer and industry sector affect deal value. The second hypothesis examines how the
financing terms change the deal value for the acquirer and target. The third hypothesis examines
how deal terms such as earn outs or milestone based compensation affect deal value. The last
hypothesis examines deal values for companies in new markets and the importance of uncertainties
and chronological acquisition order have on deal value of these acquisitions. It is the intent of this
work to provide a better framework to understand the relative influence that these internal and
external factors have on merger and acquisition deal value and terms in the context of how
acquirers or targets benefit. The following Chapters are broken down as follows: Chapter 2 is an
overview of the medical device industry and factors which impact decision making. The analysis
methods and scope of the theses are provided in Chapter 3. Results of statistical analysis for each
of the factors are given in Chapter 4. Finally, Chapter 5 is a general discussion of the results and
suggestions for future studies.
Acquisition valuations of medical device companies are not easily performed and can be quite
variable. Not surprisingly, determining if an appropriate price is paid by an acquiring company is
very difficult to assess. Accordingly, the basis of this thesis is to obtain insights into the correlation
between different internal and external target company factors that impact the deal values in
Medical Device Industry Merger and Acquisition transactions.
Chapter 2: Medical Device Industry
General Statistics
The US Medical Device Industry is the fastest growing segment of the life science industry,
accounting for approximately $75B+ in revenues in 2003 [6]. The Medical Device Industry is
expected to continue growing as the population ages in particular with the aging baby boomer
population and their more active life-styles. The growth in the percentage of individual older than
65 years of age is expected to grow from 12.5% (2000) to 20.7% (2050) [7]. In 2002 there were
approximately 8000 Medical Device firms in the United States with combined revenues of over
$75 billion dollars [7]. A significant portion (>80%) of these firms have less than 50 employees.
Similar to other life science sectors, significant resources are allocated toward research and
development (R&D) -- 5.4% to 11.4% of sales was spent on R&D from 1990 and 2002,
respectively [8] to innovate new medical device products, Fig. 1. The large expenditure in R&D
resources is unlike other manufacturing sectors, Table I. Gross margins for the industry are about
69% (medical device companies) and 54% (medical supply companies) in 2001 [6]. The average
annual growth rate over the past 10 years for medical device companies has been about 23% and
for medical supply companies about 7% [6].
0 14
au) 8- 12
0,Imt 10C S8
U 6
WC:a
a
n•
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Year
Figure 1: Research and Development (R&D) spending in the Medical Device Industry from 1990-
2002 for publicly traded companies as a percentage of sales [8].
Table I: Research and Development (R&D) Spending as a Percentage of Sales in 2002 for
Specific Industry Sectors
Industry Sector R&D spending
Pharmaceutical and Biotechnology
Medical Devices
Office Equipment
Telecom
Auto
Electrical/Electronics
Aerospace/Defense
Leisure
Metals/Mining
Paper/Forest
All Companies
**AdvaMed, The Medical Technology Industry at a Glance, 2004
as a percentage of sales (2002)
12.90%
11.40%
7.5%
5.6%
4.1%
3.9%
3.1%
1.1%
0.8%
0.5%
3.5%
Mereers and Acanuisition
With the convergence of medical technologies (including device delivery systems, biotechnology,
and pharmaceutical) in recent years, the Medical Device Industry has experienced rapid innovation.
This convergence of technologies drives M&A in the medical device industry as firms need to
acquire complementary or new technologies into their existing resources. In combination with
large expenditures on research and development programs, firms continue to acquire companies
with new technologies to access new markets or continue innovating in existing markets. Unlike
other industries, this rapid technology innovation requires the significant resources to be spent on
R&D, making it very difficult for small firms to compete directly with larger firms on broad based
platforms. Accordingly, smaller firms generally focus on single or platform product innovations in
a specific clinical or therapeutic niche and expect larger firms to recognize the potential. Once
recognized, the smaller firms usually become target firms for acquisition by larger firms.
The dynamic consolidation of firms in the Medical Device Industry by mergers and acquisitions is
driven by: (a) growth prospects in new industry sectors, (b) strategic technology acquisition to
enter new markets or complement existing product lines, (c) diversification by larger firms, (d)
complement product line offerings, (e) optimizing sales and distribution channels - Group
Purchasing Organizations (GPOs) and Independent Device Networks (IDNs) - both negotiate
purchase contracts, (f) economies of scale, and (g) economies of scope. Unlike other life science
sectors the Medical Device Industry is driven by the rapid pace of technology change. The result is
that market share and position in the industry can change quite quickly, allowing firms to leap frog
each other in position with relative easy. This requires firms to be very aggressive in developing
new markets and securing old markets. Firms continue to investigate niche technologies that may
provide access to new markets and untapped sources of revenue. Firms continue to strive to
differentiate themselves from the competition through innovation and improvements in products
and services provided through internal R&D efforts or acquired companies. Furthermore,
companies will continue to optimize product pipelines and product portfolios through internal
restructuring and external acquisitions. Companies have strong incentives to protect high
performing products and eliminate of poor performing product and R&D projects from the budget.
Moreover, as firms grow larger they continually need to find new ways to diversify and decrease
the risk related to sector industry downturns. Specifically, firms exchange focus for breadth in
order to obtain more stable stock market returns through more stability and less volatility. As a
result, firms are expected to meet the shareholder or market expectations in growth and return. The
dynamic that is created is one where active M&A transaction behavior and consolidation is present.
The active consolidation is expected to lead to more profits and less price competition.
Mergers and acquisitions in the medical device industry remains the primary exit for venture
capital backed start-up companies. Access to the public markets via Initial Public Offering (IPO)
continues to be limited to a select number of medical device companies and likely will remain a
small source of exit for firms.
Merger and acquisition transaction volumes between 1996 and 2001 are shown in Figure 2. The
number of deals that occurred during this 6 year period was relatively constant (56-82 per year).
However, the total value of the transactions has been highly variable ($3.2-27.7B). During a
similar time period the number of initial public offerings of venture backed medical device firms
has decreased significantly from 33 to 0 from 1997 to 2003. The average value of IPOs during this
time period gradually increased from almost $35.5 to $100B, excluding 2003 [9]. This IPO trend
suggests that only medical device firms with larger resources and value are able to access the
capital markets. Accordingly, most venture backed medical device firms will have a primary exit
through M&A.
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Table II are leading medical device companies that hold a significant percentage of the Medical
Device Market. Accordingly, these larger firms have begun strategic acquisitions that enable them
to access new markets/technologies and diversity their holdings. As a result of this diversification
strategy, these larger acquirers have acquired smaller firms from a variety of sector industries
within the Medical Device Industry, expanding their product portfolios. Example sectors in the
Medical Device Industry are shown in Table III.
Table II: Leading medical device companies
* Johnson & Johnson
* Medtronic Corporation
* Boston Scientific Corporation (Guidant)
* Becton Dickinson & Company
* Baxter International, Inc.
* Tyco International, Inc.
* Abbott
* St. Jude Medical
* Zimmer Holdings
* Stryker
* Biomet
Table III: Industry Sectors in the Medical Device Industry
* Cardiovascular devices * Ophthalmology devices and
* Orthopaedic devices and equipment equipment
* Dermatology, cosmetics, and wound * Surgical devices and equipment
care * Vascular devices
* Urology devices and equipment * Diagnostic imaging equipment
* Analytical equipment * Gastrointestinal devices and
* Women's health devices and equipment equipment
* Drug delivery systems * Diabetes equipment
* Patient monitoring equipment * General disposable devices and
* Diagnostic equipment and systems equipment
* Respiratory devices and equipment * Sterilization products
* Dental devices and equipment
Value creation in the Medical Device Industry
A graphical representation of a Medical Device Company life cycle is depicted in Figure 3. One
can readily see that creating and capturing value in the medical device industry is not an easy task.
Ferrari in 2005 published an article about value creation in Early Stage Medical Device companies
[ 11]. First, one has to identify a market or market niche with a clinical problem or unmet clinical
need and have the ability to develop a novel technology that will address this clinical problem.
Significant value is created if this technology has the ability to become the new gold standard of
treatment - easier, faster, more reproducible, cheaper, and with better demonstrable clinical
outcomes/benefit than the current standard of treatment. To capture this value one has to have
competitive advantages (i.e. intellectual property position, cost benefits, technological
advancement, etc...) that can be secured. However, unlike non-medical markets these technologies
must also have clear regulatory approval paths (i.e. PMA, 510(k)) and clear reimbursement
strategies. Clearly, firms that are able to identify new markets, develop novel technologies, obtain
regulatory approval, and have reimbursement for their products will have value. However, the
ability for firms to capture the full extent of that value will be dependent on the potential
sustainability of the revenue, in particular with the rapid pace of development in the Medical
Device Industry. Moreover, the ability to the firm to access sales and distribution channels in an
efficient manner will be important for value capture. Accordingly, the execution and timing of the
technology will be instrumental in the value of the company. Too slow to execute or development
at the wrong time (i.e. if other enabling technologies are required) will affect the value of the
company. Many times targeted exit strategies are Mergers and Acquisitions or an Initial Public
Offering will define the value capture by the target firm. Specifically, accessing the public markets
will provide the target firm access to the capital markets and allow the target firm access to capital
that will enable its ability to continue R&D efforts or develop and execute commercialization
strategies to generate revenue. Alternatively, merger or acquisition by a larger or equally sized
company can provide similar access to capital and resource that will allow the target firm to
continue creating value but at the expense of potentially losing control of the company.
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Figure 3: Graphical representation of a Medical Device Company life cycle.
Medical device industry unlike high-tech requires significant time for product development and
regulatory approval and accordingly need more financial resources to reach commercialization.
There are few early stage medical device firms that have diversified product lines, but rather there
are many early stage companies with one or limited number of product offerings. As a result, these
smaller firms are prime targets for acquisition by larger firms wanting to grow and expand into new
areas or expand market share in existing areas. Accordingly, smaller firms drive product
development while larger firms excel at manufacturing, marketing and sales. The result is that the
primary exit for small firms is acquisition by a large firm with a diversified portfolio and expansive
sales and distribution channels. Obstacles to growth include the complex regulatory and
reimbursement requirements in the US, the cost associated with global competition competing on
cost level, rising R&D costs and the ever increasing cost for sales and distribution channels.
Medical Device Industry Regulation - Food and Dru2 Administration (FDA) [121
The medical device industry is highly dependent on the regulatory actions of the Food and Drug
Administration (FDA) and the Department of Human Services' Centers for Medicare and Medicaid
Services (CMS). Specifically, the value of firms is highly associated with the regulatory decisions
and approvals that are granted or not granted by the FDA. Moreover, the reimbursement decisions
made by CMS can affect the cost and reimbursement of products and thus impact the value of
firms. Although there are independent third party payers, a significant number of these payers
follow the decisions made by CMS.
United States Regulation of Medical Device Products
All firms that are involved with the manufacture or distribution of medical device products in the
United States are required to register with the Food and Drug Administration (FDA). Initial
establishment registration provides the FDA with information related to the location of the
manufacturing and distribution centers and requires no fee. These firms must provide a Medical
Device Listing that includes any devices that they commercially distribute or export outside the
United States.
Medical devices sold in the United States are regulated by the FDA's Center for Devices and
Radiological Health (CDRH) division. Device classification (Class I, II, or III) was established
through the Medical Device Amendments of 1976 to the Federal Food, Drug and Cosmetic Act to
establish a mechanism for device approval based on the risk level of the device. Generally, Class I
devices are exempt from Premarket Notification 510(k) requirements. Class II devices typically
require Premarket Notification 510(k) and Class III devices more typically require Premarket
Approval in order to sell the device in the United States.
Almost 90% of all medical devices are regulated as either a Class I or II device. Examples of Class
I devices include general surgical instruments, bandages, gloves, and crutches. Most Class I
devices generally only requires the company to register with the FDA and provide the category and
classification of the device to the FDA (letter to file) prior to selling the device in the United States.
Examples of Class II devices include electro-coagulation devices, bone anchors, and soft-tissue
augmentation devices. Certain Class II devices can be placed under special controls (i.e. post-
market surveillance requirements, labeling requirements, etc...). Examples of Class III devices
include heart valves, coronary stents, and neurostimulators. Class III classification are for the
highest risk level devices (i.e. devices sustaining life or have the potential to cause significant harm
or injury, etc...) and require companies to receive Premarket Approval (PMA) prior to selling in
the United States.
Post-marketing Medical Device Reporting (MDR) is required by all firms that manufacture or
distribute medical devices. The MDR regulations provide a mechanism for the FDA and
manufactures to monitor and track major adverse events believed to be associated with approved
medical devices. This reporting system is intended to insure that firms appropriately and in a
timely manner address or correct problems associated with manufactured medical devices.
Premarket Notification 510(k)
Devices filed under a Premarket Notification 510(k) can be Class I, II, or III. Depending on the
complexity of the device response to a submission can take up to 90 days. Companies will submit
proposed labeling for the device, intended use, and directions for use of the device for approval.
These companies claim substantial equivalence to an already approved device and describe the
similarities and differences between the already approved device(s) and the device seeking
approval. Firms are required to provide engineering drawings, bench top/preclinical/or clinical
data supporting the safety and efficacy of the device. In specific instances, the FDA has prepared
guidance documents requesting specific information to be included in device submissions.
Additional standard requirements in the filing are related to the manufacturing, sterilization
validation, and software verification and validation for the device submission. If the FDA finds
substantial equivalence it will send a marketing clearance letter to the firm allowing the firm to
market the device under the approved 510(k).
Devices regulated under a Premarket Notification 510(k) generally require lower development
costs and are less complex than those devices regulated under Premarket Approval (PMA).
Accordingly, the barrier to entry for competitor companies developing devices in the same
indication is much lower both in terms of time and cost as compared to devices requiring
Premarket Approval prior to commercialization in the United States.
Premarket Approval (PMA)
Premarket Approval from the FDA is required for medical devices which may present a significant
safety risk to patients receiving therapy. Generally Class III devices require Premarket Approval
from the FDA and will undergo scientific and clinical reviews of safety and effectiveness
(including review of manufacturing processes, preclinical animal testing, bench top testing, and
clinical evaluation). Not surprisingly, the time and cost incurred by a company seeking PMA
approval is significantly greater than those only requiring Premarket Notification 510(k). The
FDA has up to 180 days to review a PMA submission but may require a medical advisory board
review before FDA approval is granted (note: the FDA is not required to follow the advice of the
medical advisory board).
Because of the more extensive requirements for a PMA submission, a PMA approval provides a
significant barrier to entry to competing firms in terms of time, cost, and clinical safety and
efficacy.
Investigational Device Exemption (IDE)
Investigational Device Exemption allows for the use of an investigational device in the clinic to
provide additional data to support a PMA of 510(k) submission. The clinical studies performed
under an IDE must be reviewed and approved by both the FDA and Institutional Review Board
(IRB) prior to initiation (note: there are instances where IRBs can grant use for devices with
significantly low clinical risk and FDA approval is not required). Pilot clinical studies, with small
clinical enrollment, may be performed prior to an IDE study to clarify safety as well as provide
feedback to procedural and clinical study development for the IDE.
FDA clearance times
The FDA clearance times for 510(k) submissions were approximately 3.2 months in 2001 while
PMA approval times took almost 14 months, Fig. 4. Not only are there significant differences in
approval times but devices that are required PMA approval are Class III devices and require
clinical trials (see above section) data. Therefore, the development and clinical trial time for
devices regulated under PMA approval are significantly longer before submissions even get to the
FDA. Accordingly, the investment costs for the development of products regulated under PMA
process are significantly higher than those under the 510(k) process.
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Figure 4: United States FDA Regulatory Approval times for (a) 510(k) Clearance and (b) PMA
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Other factors in the Medical Device Industry
Reimbursement and healthcare budgets: Medical device companies generate revenue by selling
products to health care providers. In turn, third party payers (insurance companies) reimburse the
providers for the cost of the products and procedures. Third party reimbursement and challenges in
the current health care industry budgets may begin influencing the R&D expenditures and
potentially drive consolidation in the industry. The Medicare beneficiary population is expected to
continue its growth - in 1970 there were 20.4M individuals enrolled, in 2030 it is estimated that
over 68.2M individuals will be enrolled [13].
Medicare coverage is based on two levels: National coverage and local coverage. National
coverage trumps local coverage decision on reimbursement for devices. A significant number of
the coverage decisions on devices and procedures are made at the local level. Generally, the local
coverage is based on clinical evidence or benefit and if it is a reasonable or necessary procedure.
If the device and procedure are covered by the local or national coverage decisions, payment is
provided to the provider in a bundled rate. This means that the reimbursement of the procedures
and device may not be the same as the cost of the device to the provider. The rationale for a
bundled rate is that the bundled rate is the average cost of the procedure for the standard case. As a
result, the providers must cover the cost difference. This is generally balanced by the fact that
some cases cost more and some less than the reimbursement cost by the third party payer.
Generally when new devices are introduced and they have the same indication and benefit they are
traditionally accepted under the same reimbursement plan (granted that the cost is similar).
However, for new devices or procedures which do not have an existing coverage or are
significantly more expensive than the current technologies, delays in reimbursement for these
devices and procedure can occur. In fact, some devices and procedures can be labeled
experimental or not necessary and are therefore not covered. Most other third party private
insurance companies follow the recommendations of Medicare reimbursement. Lack of
reimbursement can have a significant impact on use and therefore sales revenue for a company.
Venture Capital: Venture capital firms play a significant role in the development of medical device
technologies by providing resources to small and mid-size firms that generally have limited to no
revenues. The resources provided by Venture capital firms includes financial, management
experience, research and development, regulatory, and sales and distribution knowledge and
experience. The ability for target firms to create value (see above) in the medical device industry
in a time and capital efficient manner can be improved by having experienced management teams
that will help execute on the development plans and efficiently reach the commercialization or exit
stage of the company. Experienced venture capital firms can assist target firms in developing
strategic plans for execution, providing the target firm access to experienced management teams,
and providing the necessary capital to efficiently execute the company strategy.
Intellectual Property and proprietary know how: From 1989 to 2003 the number of medical device
patents filed per year has increased from almost 4,200 to 9,000, Fig. 5 [8]. It has become
increasingly competitive and difficult for firms to enter markets with strong IP existing. IP raises
the barrier to entry in industry sectors and has many legal ramifications as well as heavy costs
associated with the hiring of legal counsel and development of IP. Companies have competitive
advantages (including cost) with the large number of patents in the medical device field.
Challenges between lawsuits against procedural (or technique) based patents used by clinicians to
diagnose or provide treatment to patients is very difficult to pursue. However, the challenges
related to specific utility patents has becomes a large IP minefield and makes it difficult for new
entrants. Accordingly, in new markets, larger companies at times use acquisition to obtain access
to IP as well as other resources within a target company. IP is important but not necessarily a
strong barrier to entry, generally there are ways to work around.
Economies of Scale and Scope: Accessing the efficiencies that larger acquirers can provide in
manufacturing (cost), access to high trained sales forces (highly technical devices require direct
surgeon training), use of established distribution channels(access and cost), and combination with
existing product lines that are sold to or through Group Purchasing Organizations (GPOs) or
Independent Device Networks (IDNs). At the size and scale of the target companies, it is generally
very difficult for small or new entrants to compete efficiently with larger players in the market.
The acquirers provide an efficient means of growing market share of the target company products
by using resources that already exist.
Brand Identity: Brand identity is not a barrier to entry for most firms. Users are looking for
products with highest clinical benefit, easy to use, reproducible results, and lower cost of goods.
This is best illustrated by the rapid innovation and leap frog behavior of companies in market
position that is observed in the medical device industry.
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Figure 5: Medical device patents from 1989 to 2003 [8]
Exit Potential for Medical Device Companies
M&A is the primary mode of exit in the Medical Device Industry for smaller firms. In particular,
because of the high costs associated with research and development, clinical trials, and accessing
the sales and distribution channels, M&A is the most reasonable approach. Growth of the target
company revenues is generally linked to access to the sales and distribution networks that acquiring
companies have significant advantage. Conversely, growth of the acquirer into new markets with
new technologies is generally driven by the innovations provided by and executed initially through
smaller focused companies. Accordingly, the target companies will continue to find reasonable
exit values through M&A as larger acquiring companies continue to utilize their sales and
distribution assets and also require continued growth and diversification, which they can achieve
through acquisition. Moreover, due to the competitive nature of the industry, there are likely
several large acquirers with interest with each of the target companies, likely making for a
competitive acquisition environment for the target companies.
Consolidation of major players
The dynamic M&A activity in the medical device industry has resulted in consolidation of shares,
sales forces, and products within different industry sectors. This cyclic behavior of large
companies merging or large companies acquiring many smaller companies or smaller companies
being rolled up into a larger company happens across all industry sectors. Benefits for the buyers
of the products generally are interpreted as greater selection of products through a smaller number
of suppliers. The potential downside is the relative effect this may have on competition and the
relative cost of goods. One can observe that these larger entities can take advantage of 'bundling'
practices to market and sell a variety of product lines. These strategies can lead to increase in
market and sales as well as increase in margins. The underlying rationale involves the need for
larger corporations to continually refresh their product lines with new technologies. This is
beneficial to smaller firms which do not have the capital or resources to finance the marketing or
sales teams required to take advantage of the new technology. While it may be speculated that this
industry consolidation and resulting bundling behavior could lead to supplier power, the presence
of large competitor companies in fact maintains the competitive market forces. Evidence of this
can be observed by the active M&A activity over the past 10 years and the continued activity of
larger acquirers buying target firms. Large acquirers in mature market sectors will continue to
deploy resources to take advantage and enter new market niches with new cutting edge technology
driving the M&A activity in the Medical Device Industry.
An example of recent consolidation is in the cardiovascular field where the acquisition of Guidant
by Boston Scientific has reduced the large players to Boston Scientific, Abbott, Medtronic and J&J.
Similarly, in the diagnostic imaging realm with HP Medical and Acuson being acquired, Philips
Medical Systems, Siemens, and GE Healthcare are the large players dominating their industry
sector. One can look at Orthopaedics with Zimmer, Stryker, Depuy-J&J, and Sofamor Danek-
Medtronic for a similar subindustry consolidation. Finally, Medical Device distributors also have
been consolidating and the primary groups controlling large market share include Cardinal
Healthcare, Owens and Minor, and McKesson Corporation.
Concerns about consolidation?
On the provider side, the concerns are relatively tame. Specifically, although the number of
competitors is decreased with the dynamic consolidation of companies, one company generally
does not provide the best in class device in all device categories. In fact, the rapid innovations that
are observed in the Medical Device Industry have enabled smaller companies to penetrate the
market place and develop competitive market share without having the access or resources that
large companies have available. This highlights the large influence that physician champions and
key opinion leaders in each medical device sector can have on market adoption and penetration.
Physicians have tremendous influence on technology development and market adoption. They are
traditionally conservative in adopting new technologies as demonstrated by their reluctance to
switch to new technologies without clinical evidence - evidence based medicine. Generally the
thought leaders in a field are the early adopters of technology and are willing to participate in
technology development and clinical trials. Through podium speeches at national conferences and
through peer reviewed publication of clinical studies, these leaders can generate acceptance and
adoption or rejection of new devices, procedures, and approaches.
Advantages of consolidation
* Wider distribution of product - get to market faster through existing sales and distribution
channels;
* Better product information through education and clinical trials;
* Better training and education of physicians due to better service capabilities of the larger
company;
* Cost containment because groups can provide a one-stop shop by having full product
lines, resulting in less time on the buyer side;
* Benefits from the manufacturing side: unlike traditional manufacturing (i.e. automotive or
electronic/semiconductor industries), medical device manufacturing can be less predictable
or difficult to manage. Medical device product have shelf-life dates, some products require
custom manufacturing (i.e. bioprosthetic heart value sewing), and changes in design or
manufacturing practice are regulated extensively. As a result, the capital turnover in the
medical device industry is quite low (large inventories) but product liability is high.
Profile of medical device companies that are prime for acquisition [21
1. Start up medical device companies (3-7 years old) that generally are backed by private
funding or venture capital
2. New or developing medical market or market that is moving to more minimally invasive
technologies
3. New Intellectual Property/Access to new markets
4. Limited sales/revenue to date but large potential for market penetration/growth
5. Limited clinical follow up - developing new target markets/potential for growth
6. Obtained CE Mark and/or FDA approval for products
7. Reimbursement status and/or strategy well defined
What are acquirers looking for? [1, 21
1. Potential market share and position of new medical technology/platform - potential for
growth or response to shrinking opportunities for growth in current platforms
2. Clear clinical unmet need addressed by target company product or technology
3. Financial standing of company (well funded, revenues)
4. Intellectual property position to overcome or expand shortcomings of the acquirer
5. Clinical results demonstrating clear clinical benefit
6. Reimbursement status for target company product
7. Competitive technologies to acquire market share or market power
8. Complementary resources or technology to acquirer platform or product lines to overcome
shortcomings of the acquirer
9. Brand Name recognition and current market position
10. Current Management and technical staff or displacement of existing management
Summary
Unlike other industries, the Medical Device Industry is a rapidly evolving, competitive landscape
of sector industries that experiences consolidation through Mergers and Acquisitions on a frequent
and consistent basis. Inherently, the Medical Device Sector involves rapidly changing intellectual
property positions as innovative changes in medical diagnostics and therapeutics occurs. This
allows for smaller companies to rapidly react to new developments as well as target traditional
markets with technologies that provide better, easier, more reproducible, and cheaper means to
treat patients. This environment generates a fertile environment for the growth of small companies
that in large part seek venture capital funding to develop companies that can identify clinical unmet
needs, develop products that are approved by the FDA, are adopted by clinicians, and have
reimbursement at very high margins. Eventually, the company will reach a stage where exits via
M&A or IPO become attractive. Being the market leader today can change very rapidly in the
Medical Device Industry though strategic acquisition of product lines and technologies.
The dynamic M&A environment in the Medical Device Industry drives the continued growth of the
larger companies by allowing these companies to diversify and to broaden product lines. For these
larger companies that are $20B+ in value, where do you find new growth to meet shareholder
expectations? Limited growth can come from internal development, the majority of the growth
must be acquired from external sources, and therefore will drive the M&A environment.
Moreover, for companies focused in single industries (i.e. St. Jude or Zimmer) the lack of
diversification and lead to more volatile returns based on the competition. Whereas, companies
that diversify their holding (i.e. J&J, Medtronic), the relative volatility of individual Medical
Device sectors may have lesser effects on shareholder value of the parent company. The steady
stream of new companies developing products in new markets or reinvigorating older product lines
with technology development continues to provide areas of growth for the larger companies.
Furthermore, the strong cash positions of these larger companies allows for continued growth in
intellectual property position and growth in diversification into Medical Device Sector Industry.
Chapter 3: Methods
Summary:
Medical Device Industry transactions with known deal values that occurred between January 1996
and October 2006 were identified by a through search of a broad range of electronic and published
sources. There were 674 and 113 number of Mergers and Acquisitions and IPO transactions with
known deal values that were identified, respectively. For each transaction, the Food and Drug
Administration (FDA) CDRH Premarket approval (PMA) and Premarket Notification 510(k)
databases were used to identify approvals obtained pre-acquisition. Stock market returns and
market capitalization data for acquiring firms in the transactions were obtained using historical
stock quotes and data from the CRSP database. Specifics of the search methods and definitions of
terms are given in the following sections. Statistical analysis was performed using Analysis of
Variance and linear and multivariate linear regressions to determine correlations between various
internal and external factors on Medical Device M&A transaction deal values and deal terms.
Transaction Database
Merger and acquisition transactions between the period of January 1996 to October 2006 with
known deal value information were obtained (n = 674) from various data sources that included:
Database from the Center for Research in Security Prices at the University of Chicago (CRSP),
SDC Platinum/VentureX, Zephyr, and Windhover In vivo publication [14-18]. There was no
restriction to the deal value size, only that a known deal value was reported. Either the target or the
acquirer had to be a United States based entity. There was no restriction placed on the acquirer or
target having to be publicly traded (i.e. NYSE, AMES, or NASDAQ) or privately owned.
However, a significant majority of the acquirers of the target firms were indeed publicly traded
entities. Comparisons between data extracted from each of the electronic and published merger
and acquisition transactions were compared and a consolidated database generated. Transactions
with conflicting data information were examined, checked with other published sources (i.e. news
releases and 10-K filings), and corrected. The following search criteria were used for each of the
databases to obtain either M&A or IPO information:
* Deal Status: Completed
* Deal type: Acquisition, IPO, Merger
* Method of Payment: Cash, Debt, Earn out, Shares
* Deal Values: No minimum
* US SIC Classification: Surgical, medical and dental instruments and supplies
o 3841. Surgical and medical instruments and apparatus
o 3842. Orthopedic, prosthetic and surgical appliances and supplies
o 3843. Dental equipment and supplies
o 3844. X-ray apparatus and tubes and related irradiation apparatus
o 3845. Electromedical and electrotherapeutic apparatus
* Industry:
o 5100-5140 Medical Diagnostics, Medical Imaging, and Other
o 5200-5299 Medical Therapeutics, Surgical Instrumentation and Equipment, Surgical
Lasers, Pacemakers, Drug Delivery, and other Therapeutic
Electronic Databases
* ZEPHYR Database [Bureau Van DIJK Electronic Publishing: www.zephydealdata.com]:
International Mergers and Acquisitions Database with over 400,000 transactions from 1997
to present -- Covers deal records for a variety of deal types that include Mergers and
Acquisitions, Initial Public Offerings, Joint Ventures and Private Equity deals. Access:
Baker Library, Harvard Business School.
* VentureXpert Database [Thomson Financial: vx.thomsonib.com]: Database with
comprehensive coverage of venture, buyout, funds, private equity, portfolio companies,
and more. M&A and IPO Analytics for venture backed companies were obtained from this
database. Access: Dewey Library, MIT Sloan School of Business.
* SDC Platinum Databases: Thomson Financial: Mergers & Acquisitions include domestic
deals from 1979+ and international deals from 1985+. Access: Dewey Library, MIT
Sloan School of Business.
* CRSP Database: The Center for Research in Security Prices (CRSP), Graduate School of
Business, University of Chicago: Database with comprehensive coverage of stock data
from the New York Stock Exchange (NYSE), American Stock Exchange (AMEX), and
NASDAQ Stock Market (NASDAQ). All rights reserved. www.crsp.chicagogsb.edu -
Used with permission. Access wrds.wharton.upenn.edu.
Published Journal Source
In Vivo: The Business & Medicine Report, Windhover Information, Inc. 1995 to 2006;
Acquisitions: Supplies, Equipment & Devices section provides short notes on the
acquisition deal values and information related to the deal. Access: Dewey Library, MIT
Sloan School of Business.
United States FDA Regulatory Databases [12, 191
* FDA Center for Devices and Radiological Health (CDRH) Databases:
www.fda.gov/cdrh/databases
* Premarket Approvals (PMA): The FDA makes available information about releasable
PMAs in a searchable format
* Premarket Notifications (510(k)s): The FDA makes available information about
approved 510(k)s in a searchable format
Information Collected and Terms Used in the Analysis
* Merger: Pure mergers are not frequent. In fact, many acquisitions are generally described
as mergers. A pure merger involves a 1 for 1 share swap between companies.
* Acquisition: When an acquirer obtains a controlling stake (>50%) of a target company the
transaction is deemed an acquisition.
* US SIC: The SIC is a four digit Standard Industrial Classification (SIC) system used by
the United States to identify the activities of companies.
* Target: Target companies are the entity that is subject to acquisition by another entity.
* Acquirer: Acquiring companies are the entities that are taking over another company by
offering considerations for shares of the target entity.
* Deal Value (USD Mil): The value of the payment or consideration made to the Target
company by the Acquiring company. Generally the considerations used to pay are through
Cash, Share, Debt, or loans.
* Announcement Date: Date that the merger or acquisition is announced publicly
* Milestone/Earn out Payments: Payments based on achievement of milestones that include
regulatory approval or revenue levels that are included in the acquisition deal terms
* Regulatory Approval: FDA regulatory approval prior to acquisition is documented
* Venture Capital Financing: Targets with financing from venture capital firms is
documented
* Venture financing ($$): Total target financing from venture capital financing is
documented
* Target Sales: Sales of target company prior to acquisition are documented
* Acquirer Sales: Sales of acquiring company prior to acquiring the target are documented
* Acquirer Market Capitalization: Market capitalization of acquiring company prior to
acquiring target are documented
* Industry Sector: Target's main industry focus within the medical device industry
* Industry Segment Sector CAGR: Expected compound annual growth rate of industry
segment sector within the medical device industry
* PERMNO: Primary Permanent Identifier for the target or acquiring company
* Target Country: Country of business of the target company
* Acquirer Country: Country of business of the acquiring company
* Deal Status: All deals included in this analysis were COMPLETED meaning that the
Target company was legally owned by the Acquiring company. However, any earn outs or
deferred compensation or consideration may not have been completed as of the acquisition
date.
* Date of transaction: Date of transaction
* Financing of Deal: Financing of the merger and acquisition (Cash, Debt, Shares)
* IPOed prior to acquisition: Whether or not target firm had IPOed prior to acquisition
* Stock Price (-360, -30, 0, 3, 30 days): Stock price of acquiring company before and after
acquisition of the target company
* Returns: Acquirer returns following the acquisition of target company
* Chronological Acquisition or IPO information: Chronological order of acquisitions within
specified industry sectors within the Medical Device Industry
* IPO Date: Date of initial public offering
* IPO Price (USD Mil): Price of shares during initial public offering
* IPO Shares: Number of share offered during initial public offering
* IPO Amount (USD Mil): Amount of money raised during initial public offering
* Market Capitalization (USD Mil): Market capitalization of firm after initial public offering
Descriptive Statistics
M&A transactions between January 1996 and October 2006 were entered into an excel database
using the terms described in the previous section and exported to a statistical software package
(JMP, SAS Institute, Cary NC). Various descriptive statistics (i.e. mean and standard deviation,
etc...) that include analysis of deals with and without FDA approval and the type of approval, deals
where target firms reported sales prior to acquisition, deals with and without earn out terms, deals
with venture capital funding, deals where the target firm was already publicly traded, deals as a
function of industry sector were computed, and deals as a function of year were computed. In
addition, descriptive statistics for deals that included analysis of acquirer sales and market
capitalization prior to acquisition of the target firm and stock price returns for the acquirer post-
acquisition were included in the analysis. Analysis of variance was performed for individual
factors comparing deal values using year as a dummy variable.
Multivariate Linear regression model
The observed M&A deal value is thought to be a function of a number of key factors that are
associated with internal and/or external characteristics of the target company, acquiring company,
or industry behavior. In this work, the deal value is the dependent variable this is known and the
internal and external factors are the independent variables that will be analyzed. Multivariate
regression model will be used to determine the relative influence of these factors on the deal value
using the following relationship:
Log(Deal value) = coefficient*Internalfactorl + coefficient*Internalfactor2 + ... +
coefficient*Externalfactorl + coefficient*Extemalfactor2 + ...+ constant
The independent variables that were analyzed include:
* Regulatory approval type (PMA, 510(k), PMA+5 10(k), None)
* Multiple regulatory approvals (Binary)
* Date (Year)
* Target sales at time of acquisition (Binary)
* Log of Target sales at time of acquisition (USD Mil)
* Log of Acquirer sales at time of acquisition (USD Mil)
* Log of Acquirer Market Capitalization at time of acquisition (USD Mil)
* Venture backed target company (Binary)
* IPOed prior to acquisition (Binary)
* Transaction financing (Cash, Stock, Debt, Combination)
* Earn out or Milestone terms (Binary)
* Industry sector
* Acquirer returns (percentage)
Chronology of Deal within an Industry Sector
To analyze deal values in new emerging markets that have risks associated with the technology,
adoption and market penetration, and lack of information on clinical benefit, we examined four
device categories in four different industry sectors. The immaturity of the markets and regulatory
or reimbursement uncertainty can have significant influence on the deal value. Using a linear
regression model we examine the trends associated with deal values in each of these four device
categories as a function of chronological order of M&A or IPO.
Chapter 4: Results
Medical Device Industry Database Summary:
* Sample of 674 Merger and Acquisition Deals from January 1996 to October 2006, Fig. 6.
* Sample of 113 Initial public offerings from January 1996 to October 2006
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Figure 6: Number of Medical Device M&A transactions as a function of year
M&A Deal value Distribution
M&A deal values in the Medical Device database ranged from $140K to $5.5B (excluding two
deals - Guidant-BSX deal at $27B and the Gillette-PG deal at $57B'). The mean deal value was
$215.62MM and Median Deal value was $36.3MM. The asymmetry in the distribution observed in
Fig. 7a. was normalized so that a proper linear regression model analysis could be performed. A
Log transformation of the deal value provides a normal distribution of the deal value data for the
linear regression model analysis, Fig. 7b. Similar Log transformations were performed on the sales
data for the Targets and Acquiring Companies as well as on the Acquiring Company Market
' The $27B Guidant and $57B Gillette deals were excluded from the analysis as outlying deal values. All
subsequent analysis only includes the remaining 672 deals in the database.
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Capitalization data to obtain normal data distributions, Figs. 8-10. The distribution data showed
that 75% of the M&A transactions were less than $135MM, while less than 10% of the transactions
were above $500MM in value. This suggests that a significant portion of the M&A transaction
deal values in the Medical Device Industry are generally modestly valued transactions and not the
multi-million or billion dollar transactions that are well publicized in the press.
Average Size of Acquirer
Average size of the acquirers based on sales and market capitalization information that were
publicly available. Note: the number of acquisitions by the top companies, Fig. 7, skews the
average acquirer sales and market capitalization data and can be observed by the large standard
deviations in the values. The acquirer sales data were available for 500/674 of the companies in
the database and was $6.66 ± 17.95B with a median value of $442.05MM, Fig. 8. The minimum
and maximum acquirer sales were $0.44MM and $13.07B, respectively. The distribution data for
acquirer sales shows that 75% of the acquiring companies had sales of less than $3.5B at the time
that the target company transaction occurred. The mean market capitalization data were available
for 440/674 of the companies in the database and was $20.05 + 53.08B with a median value of
$922.90MM, Fig. 9. The minimum and maximum market capitalization values were $2.92MM
and $521 B, respectively. The distribution data for acquirer market capitalization shows that 75%
of the acquiring companies had market capitalization at the time of the acquisition of less than
$12B at the time that the target company transaction occurred. The significant variation in acquirer
sales value and acquirer market capitalization value is indicative of the large number of M&A
transactions that are undertaken by the largest of the medical device companies.
Target Company Sales
Of the 672 firms in the M&A database, 551 of these firms had sales and 121 of the firms had either
no sales or sales status was unknown. Of these 551 firms with sales 215 of these firms had reported
sales, Fig. 10. Target firms that reported sales had a mean deal value of $256.27 + 616.42MM as
compared to Target firms without reported sales values which had a mean deal value of $30.51 ±
44.97MM. Firms with sales had significantly larger deal values as compared to firms without
sales. The mean target sales for the 215 firms were $146.28 ± 406.92MM.
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Figure 7: Graphical representation of (a) Histogram of the Medical Device deal values for
companies less than $250MM showing asymmetric distribution in deal values, (b) Log
transformation of all deal values to obtain a normal distribution for the linear regression model.
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Figure 8: Graphical representation of (a) Histogram of the acquirer sales values for companies
with less than $1B showing asymmetric distribution of acquirer sales, (b) Log transformation of the
acquirer sales for all companies to obtain a normal distribution for the linear regression model.
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Figure 9: Graphical representation of (a) Histogram of the acquirer market capitalization for
companies less than $2B showing asymmetric distribution in market capitalization of acquirers, (b)
Log transformation of the market capitalization values to obtain a near normal distribution for the
linear regression model.
/
I I I I I
0 50 100 150
Target Sales ($MM)
200 250
I I I I
i-rzzzzzzE
(b) Log(Target Sales)
Figure 10: Graphical representation of (a) Histogram of the target companies reporting actual
sales numbers for companies less than $250MM in sales showing asymmetric distribution of sales,
(b) Log transformation of the sales values to obtain a near normal distribution for the linear
regression model.
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Internal and External Factors Affecting Deal Value:
Medical device companies create value and maximize sale value through both external and internal
factors [11, 20]. Internal factors such as access to financial resources (cash), achievement of
internal milestones (regulatory approval, clinical or preclinical milestones, initial sales), amount of
sales revenue, management abilities, and individual preferences (risk tolerance), all can have
impact on the value of the target company. Lack of adequate information on the clinical and
preclinical milestone of individual companies, analysis of value based on these factors was not
performed. Venture capital funding is used as a proxy to judge financial resources, management
abilities and individual preferences. Target companies that have access to Venture capital funding
for the most part tend to have a more sophisticated approach to management and higher tolerance
for risk-return as well as have a certain level of financial resources to fund target companies.
Accordingly, target companies with venture funding versus target companies without venture
funding are expected to be able to create higher value. Additionally, because Medical Device
products are regulated by the FDA companies that secure regulatory approval for their products
will increase the value of their company. Accordingly, we analyze the effect of regulatory
approval as well as the affect of having multiple products approved on the valuation of a target
company. Finally, target companies are able to demonstrate not only that a market exists but that
there is market adoption of the product(s) that the company has developed by showing sales
revenues.
It is expected that target companies that demonstrate sales revenues will have higher deal values.
External factors such as comparable M&A valuations, ability to access the capital markets for exit
or access to capital, and multiple buyers influence the potential deal value of the target. Note:
information on the number of bidders for a particular Medical Device Target Company transaction
was limited and therefore not accounted for in this analysis. In addition, factors such as
characteristics of the acquirer (i.e. acquirer sales or acquirer market capitalization at the time of
acquisition) may influence the final deal value. Furthermore, market conditions such as over
valued stock of an acquiring company may lead to differences in transaction value of the M&A.
Other factors include the time of the transaction (Year), the industry sector that the transaction has
occurred (comparable transactions within sectors may drive up or drive down the deal values), and
ability to access the public markets through an IPO offering may have influences on the deal value
and are therefore considered in the multivariate regression models.
External factors
Medical Device Industry Transactions and Mean Deal Value
The average number of M&A transactions has increased from 40 ± 16 to 79 ± 12 between the
periods of 1995-2000 and 2001-2006, respectively, Table IV. There does not appear to be a linear
correlation between transaction year and the mean deal value of the transaction. A linear
regression of year and Log(deal value) generated the following fit: Log(Deal Value) = 77.69 -
0.04*Date(Year) with an RA2 value of 0.02. The regression fit showed that date (year) was
significantly associated with Log(deal value) and had a negative correlation between 1996 and
2006. The number of M&A transactions over the past 5 years has been relatively stable. This is
reflective of the fact that M&A remains an active and primary exit transaction for medical device
companies. The relative stability in the number of transactions demonstrates that consolidation
through M&A will be a consistent feature of the industry.
Table IV: Number of Medical Device Industry Transactions and Mean Deal Value as a Function
of Year
Mean Deal Value Stdev Deal Value
Year Number of Deals ($MM) ($MM)
1996 31 122.68 184.48
1997 30 348.24 524.47
1998 44 601.06 1025.91
1999 27 157.25 225.54
2000 66 205.43 569.23
2001 74 204.24 548.70
2002 71 90.01 284.40
2003 86 114.65 288.34
2004 73 272.98 626.06
2005 100 159.42 510.48
2006 70 273.77 748.80
If we take a more in depth look at the individual sectors within the Medical Device Industry we can
see that mean deal value is highly variable, Table V. The largest number of M&A transactions
occurred in Cardiovascular Devices, Orthopaedic Devices and Equipment, and Diagnostic
Equipment sectors, 93, 74, and 79 transactions between January 1996 and October 2006,
respectively. The largest mean deal values have been generated in Diabetes Equipment ($1.2B)
and Gastrointestinal Equipment ($608MM). Diabetes Equipment was shown to have significantly
higher mean deal values than Surgical Equipment, General Disposable Equipment, Diagnostic
Equipment and Systems, Urology Devices and Equipment, Dermatology, Cosmetics, and
Woundcare, Neurology Devices, and Patient Monitoring Equipment (p<0.05). However all other
mean deal value comparisons between industry sectors as a function of acquisition year were not
significantly different (p>0.05). The OLS regression model shows that there is statistical
significant relationship between deal value and several of the independent variables, Table VI.
Diabetes Equipment, Diagnostic Imaging, and Patient Monitoring Equipment all show statistical
significant relationships at the 5% level with Log (Deal Value).
Table V: Mean Deal Values for the Various Medical Device Industry Sectors
Industry Sector Number of Mean Deal Stdev Deal CAGR 2004
M&A Value Value ($MM) 2004- Revenues
Transactions ($MM) 2011* ($B)*
Analytical Equipment 12 100.38 145.00
Cardiovascular Devices 93 191.76 458.79 16.8% 14.86
Dental Equipment 33 195.09 428.48
Dermatology, Cosmetics and
Woundcare 19 55.20 65.79 6.2% 5.89
Diabetes Equipment 14 1162.76 1221.95 7.9% 2.09
Diagnostic Equipment and Systems 79 127.13 455.73
Diagnostic Imaging 50 360.88 731.98
Drug Delivery Systems 13 112.83 130.83
Gastrointestinal Equipment 6 607.67 1271.60 4.1% 0.77
General Disposable Equipment 38 129.63 260.83 23.8% 2.57
Neurology Devices 21 174.87 379.69 12.3% 1.29
Oncology Equipment 16 85.72 132.86
Ophthalmology Devices and
Equipment 26 220.82 363.91 3.2% 3.75
Orthopaedic Devices and Equipment 74 247.26 650.06 13.3% 12.52
Other (Biomaterial, ENT, Hearing,
Nephrology, Pain management) 17 101.04 205.68 11.6% 4.54
Patient Monitoring Equipment 27 125.38 387.45
Respiratory Equipment 20 199.72 432.16 4.9% 1.08
Sterilization Products 6 22.18 25.15 5.6% 0.75
Surgical Equipment 44 284.76 722.41 5.8% 8.90
Urology Devices and Equipment 20 78.08 125.22
Vascular Devices 30 333.60 1002.23
Women's Health Devices 14 111.31 140.36
*Frost and Sullivan US Medical Device Market Outlook May 24, 2005
IPO market
The number of Medical Device Companies that had access to the public markets through Initial
Public Offerings has changed over the years, Fig. 11. Between 1996 and 2000 there was an
average of 14 companies IPOing each year. This trend has decreased significantly over the past 5
years, now between 2001 and 2006 there are an average of about 7 companies IPOing per year.
Not surprisingly, the number of M&A transactions has consistently grown during the same time
periods. This trend further demonstrates that M&A and not IPOs continue to be the primary form
of exit for early stage or smaller medical device companies. It is worthy to note that although there
has been a drop in the average number of IPOs between the periods of 1996-2000 and 2001-2006,
the average money raised has increased from $36MM to $66MM over the two time periods.
Table VI: Deal value as a function of the Medical Device Industry sectors. The OLS Regression
model uses Log (Deal Value) as the dependent value and Date (Year) and Industry Sector as the
independent values. Women's Health sector is the base comparison sector in the model.
Term Estimate Std Error
Intercept 71.8322* 21.4137
Date (Year) 
-0.0351* 0.0107
Analytical Equipment 0.0160 0.2163
Cardiovascular Devices 0.1393 0.0858
Dental Equipment -0.0361 0.1339
Dermatology, Cosmetics and
Woundcare -0.2599 0.1734
Diabetes Equipment 0.8307* 0.2007
Diagnostic Equipment and Systems -0.1502 0.0921
Diagnostic Imaging 0.2506* 0.1111
Drug Delivery Systems -0.0009 0.2081
Gastrointestinal Equipment 0.5349 0.3032
General Disposable Equipment -0.1206 0.1264
Neurology Devices -0.2859 0.1653
Oncology Equipment -0.0470 0.1882
Ophthalmology Devices and
Equipment -0.0447 0.1500
Orthopaedic Devices and Equipment 0.0217 0.0939
Other (Biomaterial, ENT, Hearing,
Nephrology, Pain management) -0.2439 0.1828
Patient Monitoring Equipment -0.3487* 0.1469
Respiratory Equipment 0.1439 0.1692
Sterilization Products -0.3311 0.3043
Surgical Equipment -0.0387 0.1176
Urology Devices and Equipment -0.2536 0.1692
Vascular Devices 0.2552 0.1401
*Statistical 
significance 
at 5%
Note: Log(Deal Value)= b + m*y + g(i)*x(i); where g(i) is the coefficient, x(i) is binar
y 1 or 0 and 
i is the sector 
ID;
It is more interesting to examine firms that have had access to the public markets and have been
involved in an M&A transaction with another company. Table VI shows M&A deal values for
companies that IPOed prior to a M&A transaction as compared to companies that did not IPO prior
to the M&A transaction. Target firms that IPOed prior to a Merger or Acquisition with an
acquiring company was shown to have significantly higher deal value (p<0.05) than firm that had
not accessed the public markets. Specifically, 94 firms in the database were shown to have
accessed the public markets and had mean deal values of $384.8 ± 669.4 MM as compared to the
578 firms that did not access the public markets and had mean deal values of $332.3 + $2662.3
MM. Firms that have IPOed prior to the M&A transaction generally have products or
technologies that are more mature and have already achieved regulatory and sales milestones prior
to the transaction. Moreover, the valuation of these firms is likely more transparent and based on
revenue multiples that are more reliable than companies that do not have publicly available data.
The question is whether or not the returns for acquirers are larger for transactions that involve
companies that have IPOed versus companies whose information is less transparent to the public
(non-IPOed companies). Correlating M&A transactions of companies that have IPOed prior to
M&A and those that have not with 30 day acquirer returns showed no difference in returns
(p>0.05). Furthermore, there was no statistical significance in 30 day acquirer returns for Small
Cap, Medium Cap, Large Cap, or private companies when acquiring targets which were public
versus private (p>0.05 in all instances).
Multiple buyers/bidders for a target company can create an auction environment that leads to
premium pricing of a target company as compared to M&A transactions that only involve one
bidder. As a result of having multiple bidders there are reasons that are not associated with value
creation that can affect the target company M&A transaction value that are not associated with the
valuation of the target company. Unfortunately, in this work we were not able to obtain sufficient
data on firms to provide an accounting of the degree in which multiple bidders may or may not
have influenced the transaction deal values in our analysis.
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Figure 11: Graphical representation of (a) Number of Medical Device Industry IPO transactions
and mean amount of money raised as a function of year and (b) Comparison between the number of
Medical Device Industry IPO and M&A transactions as a function of year.
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Table VII: Mean Deal Value as a function of Year for firms that IPOed versus NO IPO prior to
No IPO prior to M&A transaction IPOed prior to M&A transaction
Number of Mean Deal Stdev Deal Number of Mean Deal Stdev Deal
transactions Value Value transactions Value Value
($MM) ($MM) ($MM) ($MM)
1996 21 68.29 81.12 10 236.90 278.25
1997 23 304.51 489.81 7 491.95 646.83
1998 35 581.35 1011.80 9 677.71 1139.29
1999 20 108.34 167.27 7 297.00 317.91
2000 58 200.76 602.81 8 239.27 219.89
2001 64 174.13 449.74 10 396.97 989.16
2002 64 91.73 297.52 7 74.22 117.79
2003 79 121.81 299.78 7 33.90 34.63
2004 64 238.78 615.51 9 516.15 684.29
2005 92 102.84 393.31 8 810.16 1071.63
2006 58 254.36 800.71 12 367.59 428.13
Totals 578 94
Acquirer Size
Acquirer size was measured using both sales revenues and market capitalization of the acquirer at
the time of target acquisition, Table VIII. Large Cap companies ($5B+) pay more for target
companies than either the smaller Cap companies or the private companies (p<0.05). Similarly,
Medium Cap companies ($1-5B) pay more than Private, small cap and micro cap companies
(p<0.05). Private and Small Cap ($250MM-1B) companies are shown to pay more than Micro cap
(<$250MM) companies (p<0.05) for these M&A transactions, Table VIII. This analysis suggests
that large cap companies in the Medical Device Industry pay more to acquire companies. Possible
rationales for this behavior include: (a) larger cap companies have more financial resources or tend
to have stocks that are higher valued, enabling the larger cap companies to spend more on M&A
transactions, (b) larger cap companies tend to acquire companies that are in more mature stages
(i.e. post-regulatory approval, larger sales revenue), (c) larger cap companies tend to use different
deal terms that change the value of the M&A transaction (i.e. stock versus cash, use of earn out
terms).
M&A transaction
Table VIH: Size of Acquiring companies and the Associated Mean Deal Values of the Companies
Acquirer size Number Mean Deal Value Stdev Deal Value
($MM) ($MM)
Private Company 174 177.04 430.10
Large Cap. Company 159 470.12 908.07
Medium Cap. 99 213.167 456.17
Company
Small Cap. Company 122 93.77 321.69
Micro Cap. Company 118 57.64 179.45
Multivariate linear regression using transaction year, Log(acquirer sales) and Log(acquirer market
capitalization) parameters was performed. The regression model was: Log(Deal Value) =
0.15*Log(Market Capitalization) + 0.24*Log(Acquirer Sales) - 0.04*Date(Year) + 88.57 with an
R^2 value of 0.30, Table IX. All three parameters were statistically significant, demonstrating a
positive correlation between size of the acquirer and the deal values associated with M&A
transactions. To examine whether or not larger cap companies are associated with more mature
target companies multivariate linear regression was performed using date, regulatory approval and
target sales as the independent variables. The large market cap companies were positively
correlated with target sales and were statistically significant at 5% levels. However, year and
regulatory approval were not statistically significant variables with respect to the dependent
variable (market cap). To evaluate whether larger market cap companies tend to use different
financing or earn out terms in the M&A transactions a multivariate linear regression was performed
using date, financing terms, and earn out terms as the independent variables. Financing deal terms
based on cash were shown to be statistically significant and positively correlated with acquire
market cap. These results suggest that larger market cap companies not only have larger financial
resources but tend to acquire more mature target companies, and tend to pay cash in M&A
transactions.
An interesting question is whether larger cap companies have higher stock returns for the larger
deal transactions as a result of acquiring more mature target companies. To evaluate this we
examined acquirer stock price returns at 30 days post-transaction date and compared it with
acquirer market cap and M&A transaction deal value. A multivariate linear regression analysis
was performed and the following regression model was computed: Log(Deal value) = -
1.43*returns + 0.34*Log(Market cap) - 0.04*Date(Year) + 89.28 with an RA2 value of 0.27. There
was no significant effect observed between deal value and 30 day returns for the acquirer.
Date(year) and Log(Market cap) were both statistically significant variables, Table X. This
suggests that acquirer stock price returns at 30 days is not associated with M&A transaction deal
value. In fact, the results show that there is a negative correlation with stock price returns and deal
value. Multivariate regression modeling with 30 day returns as the dependent variable and
Date(year) and Market Cap segment as the independent variables showed no statistical
significance. Therefore, 30 day returns were not associated with individual company market cap.
Table X: Deal value as a function of the Acquirer Characteristics and 30 Day returns. The OLS
Regression model uses Log (Deal Value) as the dependent value and Date (Year), Acquirer Market
Cap and 30 day returns.
Term Estimate Std Error
Intercept 89.2807* 26.8197
Date (Year) 
-0.0443* 0.0134
Log (Market Cap) 0.3446* 0.0341
Returns 
-1.4291 1.0982
*Statistical significance at 5%
Note: Log(Deal Value) = b + m*Date(Year) + cl *Log(Market Cap) + c2*Returns;
Table IX: Deal value as a function of the Acquirer Characteristics. The OLS Regression model
uses Log (Deal Value) as the dependent value and Date (Year), Acquirer Market Cap and Acquirer
Sales.
Term Estimate Std Error
Intercept 88.5711* 24.4523
Date (Year) -0.0439* 0.0122
Log (Market Cap) 0.1468* 0.0634
Log (Acquirer Sales) 0.2437* 0.0641
*Statistical significance at 5%
Note: Log(Deal Value) = b + m*Date(Year) + cl *Log(Market Cap) + c2*Log(Acquirer Sales);
An argument that has been made is that acquiring companies with overvalued stock tend to use
stock as payment and will pay more for the M&A transaction. To evaluate this argument, a
multivariate regression model was performed to examine if there is a correlation between 360 day
returns (to evaluate if a stock is overvalued), deal value of the transaction, and financing type. The
only factor which had a statistically significant impact on deal value was financing type of the deal.
There was no statistically significant difference in deal value and 360 day returns or differences in
the returns as compared to the S&P composite index. A negative correlation between 360 day
acquire returns was found. This suggests that for the Medical Device Industry M&A transactions
in our database, the correlation between overvalued stocks and deal value were not observed. But
the negative correlation between the 360 day returns and acquisition may suggest that M&A
acquisitions do not benefit the acquirer with respect to market returns.
We also examined whether or not acquirers experience abnormal returns as a result of the M&A
transaction using a three day event window at the time of acquisition of a target firm. Statistical
significant differences in the 3 day event window for firms was found as compared to S&P
composite index over the same period, 0.4% versus -0.008% for the acquirers (p<0.05). This
suggests that shareholders of the acquiring company can benefit with minor abnormal returns as a
result of the M&A transaction. Interestingly, market cap is not significantly associated with returns
over the 3 day event window or returns as compared to the S&P composite index over the same
period. This suggests that large and small firm M&A transaction announcements do not have
different impacts on the abnormal returns that an acquiring firm may observe. Perhaps this is
slightly counter intuitive because one would think that abnormal returns from M&A transactions
would benefit smaller firms more than larger firms.
Acquirer Diversification
Table XI represents a sampling of the top 25 acquirers based on the number of acquisitions in our
database. Immediately one observes that the top medical device companies have made a
significant number of acquisitions between January 1996 and October 2006. Moreover, these
larger firms acquisitions tend to be from several different industry sectors, as indicated by the
number of diversified acquisitions. For example, Medtronic has made acquisitions in
Cardiovascular Devices, Gastrointestinal Equipment, Orthopaedic Devices and Equipment,
Neurology Devices, Vascular Devices, Diagnostic Imaging, Drug Delivery Systems, Urological
devices, and several additional sectors. Other firms such as Abbott, Boston Scientific, J&J, and
Tyco Healthcare have done similar diversifying acquisitions. Some suggest that these diversifying
acquisitions enable firms to enter new markets that can reduce volatility in their share price but also
drive growth and meet market expectations. In addition, these acquisitions may allow the acquirer
to better utilize complementary resources that include technology, manufacturing capabilities, and
sales and engineering talent. However, the benefits of acquire diversification and market returns
is less convincing. Specifically, in an efficient market investor have the ability to perform their
own diversification of assets and therefore companies should not benefit from market
diversification. In the previous results section we demonstrated that the 30 day returns were not
associated with deal value but were statistically significant with respect to date and acquirer market
cap.
Table XI: Top 25 Companies Based on Number of Acquisitions Between 1996 and 2006*
Company Number of Mean Deal Value Stdev Deal Value
acquisitions ($MM) ($MM)
(No. diversified
acquisitions)
Medtronic Inc. 23 (13) 594.56 1151.10
Boston Scientific Corporation 21 (10) 263.02 502.75
Inverness Medical Innovations 20 (1) 43.66 47.35
Inc.
Integra Lifesciences Holdings 15 (5) 30.72 36.93
Corporation
Abbott Laboratories Inc. 14(5) 790.12 1428.29
St Jude Medical Inc. 13 (5) 279.58 336.61
DENTSPLY International Inc. 11 (1) 101.07 155.01
Cooper Companies Inc., The 10 (5) 129.84 342.02
Johnson & Johnson 10 (8) 641.13 1073.65
Tyco Healthcare Group LP 10 (7) 1394.12 1598.07
Guidant Corporation 9 (2) 199.24 251.31
Edwards Lifesciences 8 (2) 29.25 39.18
Corporation
GE Medical Systems 8 (2) 538.59 779.17
OSI Systems Inc. 8 (1) 12.81 15.20
American Medical Systems 7 (1) 158.00 259.74
Holdings Inc.
Baxter International Inc. 7 (4) 202.99 136.66
Coherent Inc. 7 (3) 73.11 134.82
Philips Medical Systems 7 (2) 817.29 564.79
Stryker Corporation 7 (2) 326.36 695.52
DePuy AcroMed Inc. 6 (1) 165.92 126.00
Varian Medical Systems Inc. 6 (1) 20.92 10.29
Advanced Neuromodulation 5 (1) 15.69 19.57
Systems Inc.
Becton Dickinson & Company 5 (4) 170.34 213.71
CONMED Corporation 5 (4) 106.86 149.45
Cantel Medical Corporation 5 (4) 37.04 38.31
*These are acquisition that had publicly reported deal values
Internal factors
Influence of Venture Capital Financing
Venture capital funding in Medical Diagnostics, Medical Therapeutics, and Medical/Health
Products has been very active between January 1996 and October 2006 accounting for almost 5000
deals totaling over $32B in financing, Table XII [17]. Slightly over 4000 company financing have
been funded during that period of time with an average slightly under $8M per company. The
relative sum and size of investments in the Medical Device Industry from venture capital sources
has been relatively constant since 2000. This can be compared with venture funding for all
industries over the same period: over 93,000 deals in over 78,000 companies for a sum investment
of almost $950B over the past 10 years. Although medical device investments are only a small
portion of the overall venture capital investment, the returns and relative importance of Medical
Device Industry continues to grow.
Table XII: Venture Financing from January 1996 to October 2006 for Selected Medical
Diagnostic, Therapeutic, and Medical/Health Product Companies.
Avg Avg Avg
Per Per Per Sum
Company Deal Comp Firm Inv.
Disbursement No. of No. of No. of (USD (USD (USD (USD Pct of
Year Deals Comp Firm Mil) Mil) Mil) Mil) Inv
1996 344.00 264.00 253.00 3.27 4.27 4.45 1,126.48 3.49
1997 386.00 300.00 322.00 4.10 5.28 4.92 1,583.34 4.91
1998 421.00 340.00 310.00 5.24 6.49 7.12 2,206.59 6.85
1999 424.00 354.00 342.00 6.04 7.23 7.49 2,561.14 7.95
2000 500.00 429.00 479.00 7.35 8.56 7.67 3,673.20 11.40
2001 447.00 384.00 461.00 7.48 8.70 7.25 3,341.53 10.37
2002 380.00 322.00 442.00 7.06 8.34 6.07 2,684.02 8.33
2003 495.00 414.00 496.00 6.85 8.19 6.84 3,391.34 10.52
2004 506.00 411.00 534.00 9.31 11.47 8.83 4,712.64 14.62
2005 577.00 462.00 557.00 6.31 7.88 6.53 3,639.66 11.29
2006 435.00 383.00 459.00 7.61 8.65 7.22 3,311.74 10.27
Total 4,915.00 4,063.00 4,655.00 6.56 7.93 6.92 32,231.68 100.00
* Thompson Financial: Investment Analytics Report
More interestingly, one can examine the influence of venture capital investments in the medical
device industry to determine if there is value created through the investment. Specifically, if the
value that venture capital provides, from a 10,000 foot level, is measured by target firm M&A
transaction deal values. Of the 672 firms analyzed, 205 of the target firms had venture capital
backing and 467 firms did not have a record of venture capital backing listed in the Thompson
Financial database between 1996 and 2006, Fig. 12. There is statistical significant difference
between deal values for firms without venture capital funding as compared to those with venture
capital funding (p<0.05), the mean deal value for firms with venture capital funding were higher
than those without ($246.8 ± 556.1MM and $201.9 ± 569.1MM, respectively). This suggests that
firms with venture capital funding not only have access to capital resources but access to better
management experience, better product development and commercialization experience, and access
to individuals who can develop and help execute strategic plans in a time and capital efficient
manner.
Regulatory Approval
To understand the potential influence that having regulatory approval has on M&A deal value, 672
firms were examined to determine if target firms obtained regulatory approval prior to acquisition,
if there were more than one type of regulatory approval, if there were multiple regulatory
approvals, and if the deal value was associated with regulatory approval requirements within
specific sectors of the medical device industry. Of the 672 firms in the database, 38 firms were
identified to have obtained both PMA and 510(k) approvals prior to acquisition, 26 had PMA
approval, 295 had 510(k) approval and 281 firms either did not require FDA approval or had not
obtained approval prior to target firm acquisition. The mean deal values for firms with regulatory
approval are shown in Fig. 13. When accounting for Date(year), the deal values for target firms
with both (PMA and 510(k)) or just PMA approvals have significantly higher deal values than
firms with only 510(k) or No approvals (p<0.05). Finally, target firms with 510(k) approvals also
have deal values greater than firms with no approvals either required or issued (p<0.05).
Similarly, firms with multiple regulatory approvals (more than one - i.e. two or more-510(k) or
two or more-PMA, one 510(k) and one-PMA, etc...) had significantly higher deal values that firms
with one or no regulatory approvals (p<0.05), Table XIII.
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Figure 12: The number of Medical Device M&A transactions that venture and non-venture
backed companies as (a) a function of year and (b) mean deal value.
Correlations between deal value and regulatory approval were also examined for each industry
sector, Table XIV. This is important because each industry sector may have different value on the
regulatory status of the devices. For example, many of the cardiovascular devices are Class III
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devices and therefore require PMA approval whereas many Orthopaedic devices are Class II
devices and for the most part only require 510(k) clearance. As a result, deal value may vary
between industry sectors based on the type of regulatory approval obtained. Cardiovascular
Devices showed that transactions with PMA approval had statistically significant higher deal
values than those with only no approval (p<0.05), but no difference with deal having only 510(k)
approval (p>0.05). The mean deal values in the Cardiovascular Device Sector were ranked:
Both>PMA>510(k)>None. Ophthalmology Devices showed that deal values with PMA approval
were statistically significantly higher than deal values with only 510(k) approval (p<0.05), however
not significantly different than deal with no approvals (p>0.05). The mean deal values in the
Ophthalmology Devices Sector were ranked: PMA>None>510(k). Orthopaedic Devices showed
that deal values for target firms with Both (PMA and 510(k)) were statistically significantly higher
than firms with only PMA, 510(k) or no regulatory approval (p<0.05). The mean deal values in
Orthopaedic Devices Sector were ranked: Both>510(k)>PMA>None. In the combined Other
Sector (includes Biomaterial, ENT, Nephrology, Pain and Hearing Device Companies) deal values
for target firms with 510(k) approval were statistically significantly higher than firms with no
approval (p<0.05). The mean deal values in the Other Sector were: 510(k)>Both>PMA>None.
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Figure 13: Medical Device Industry deal value as a function of type of regulatory approval
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Table XIII: Medical Device Industry M&A transaction with Multiple Regulatory Approvals and
the associated Mean Deal Values
Multiple Regulatory Number Mean Deal Value Stdev Deal Value
Approvals ($MM) ($MM)
Y 317 302.09 711.04
N 353 138.72 376.95
Unknown 2 84.78 113.46
Table XIV: Type of Regulatory Approval for the different Medical Device Industry Sectors
Type of Regulatory Approval
Industry Sector Total Number PMA+510(k) PMA 510(k) None
Analytical Equipment 12 0 0 2 10
Cardiovascular Devices 93 5 9 35 44
Dental Equipment 33 0 0 17 16
Dermatology, Cosmetics and Woundcare 19 1 0 11 7
Diabetes Equipment 14 2 0 6 6
Diagnostic Equipment and Systems 79 3 2 29 45
Diagnostic Imaging 50 1 1 29 19
Drug Delivery Systems 13 0 0 4 9
Gastrointestinal Equipment 6 0 0 5 1
General Disposable Equipment 38 1 0 20 17
Neurology Devices 21 2 2 9 8
Oncology Equipment 16 0 0 9 7
Ophthalmology Devices and Equipment 26 0 2 7 17
Orthopaedic Devices and Equipment 74 8 2 31 33
Other 17 1 1 5 10
Patient Monitoring Equipment 27 0 0 12 15
Respiratory Equipment 20 2 1 11 6
Sterilization Products 6 0 0 2 4
Surgical Equipment 44 3 2 21 18
Urology Devices and Equipment 20 3 3 7 7
Vascular Devices 30 5 0 15 10
Women's Health Devices 14 1 1 8 4
Sales and Revenue:
Target firms that reported sales had a mean deal value of $256.27 ± 616.42MM as compared to
Target firms without reported sales values which had a mean deal value of $30.51 ± 44.97MM.
Firms with sales had significantly larger deal values as compared to firms without sales (p<0.05).
The mean target sales for the 215 firms were $146.28 ± 406.92MM. A multivariate regression
model was performed with Date(Year), Sales Prior to M&A (binary), and Industry Sector with
Deal value. Date (Year) and having target sales prior to M&A were statistically significant
association with deal value, Table XV. The industry sectors with statistically significant
correlation with sales and deal value were Cardiovascular Devices, Diabetes Equipment,
Diagnostic Imaging, and Patient Monitoring Equipment. All other industry sectors were not
significantly associated with deal value, Table XV.
Table XV: Deal value as a function of the Medical Device Industry sectors and Target Sales. The
OLS Regression model uses Log (Deal Value) as the dependent value and Date (Year), Industry
Sector, and Target Sales prior to acquisition as the independent values. Women's Health sector is
the base comparison sector in the model.
Term Estimate Std Error
Intercept 64.4717* 20.5360
Date (Year) -0.0315* 0.0103
Target Sales (Y/N) -0.2908* 0.0378
Analytical Equipment 0.0583 0.2073
Cardiovascular Devices 0.1920* 0.0825
Dental Equipment -0.0845 0.1285
Dermatology, Cosmetics and -0.2965 0.1662
Woundcare
Diabetes Equipment 0.8161* 0.1923
Diagnostic Equipment and Systems -0.1434 0.0882
Diagnostic Imaging 0.2669* 0.1064
Drug Delivery Systems 0.0366 0.1994
Gastrointestinal Equipment 0.4343 0.2907
General Disposable Equipment -0.1392 0.1211
Neurology Devices -0.2197 0.1586
Oncology Equipment -0.1117 0.1805
Ophthalmology Devices and 0.0161 0.1439
Equipment
Orthopaedic Devices and Equipment 0.0165 0.0900
Other (Biomaterial, ENT, Hearing, -0.2748 0.1751
Nephrology, Pain management)
Patient Monitoring Equipment -0.2771* 0.1410
Respiratory Equipment 0.1306 0.1621
Sterilization Products -0.2457 0.2917
Surgical Equipment -0.0839 0.1129
Urology Devices and Equipment -0.2944 0.1621
Vascular Devices 0.2501 0.1342
*Statistical significance at 5%
Note: Log(Deal Value) = b + m*y + n*z + g(i)*x(i); where g(i) is the coefficient, x(i) is binary I or 0 and i is the sector
ID;
Transaction Financing
Transaction financing for 525 out of the 674 deals was available for analysis, Table XVI. 430 of
the deals involved cash and had a mean deal value of $205.41 ± 538.54MM. 165 of the deals
involved stock and had a mean deal value of $297.22 + 782.44MM. 42 of the deals involved debt
and had a mean deal value of $393.36 ± 844.86MM. No statistical significance between the
different methods of financing listed in Table XVI. Nor was there statistical difference in deal
value for deals that involved either cash and/or stock financing. However, deal that involved debt
financing did have significantly higher deal values as compared to those with purely cash or stock
(p<0.05). Although the difference in deal value between transactions that involved cash as
compared to transactions that involved stock were not statistically significant, the higher overall
mean value for transactions involving stock suggests that these deals are priced higher potentially
compensating for the stock overvaluation or perhaps since larger firms tend to use stock more often
are simply priced higher.
Table XVI: Medical Device Deal Financing Type and the Associated Mean Deal Values
Mean Deal Value Stdev Deal Value
Deal Financing Number of Deals ($MM) ($MM)
Cash 330 192.36 519.13
Cash & Stock 64 195.97 515.53
Cash & Debt 30 388.22 783.72
Stock 89 355.34 898.93
Stock & Debt 6 702.49 1436.34
Cash, Debt & Stock 6 109.91 127.59
Unknown 147 141.04 173.85
Earn outs and Returns
Of the 672 transactions 172 of these transactions involved milestone payments that were likely
associated with milestones such as regulatory approval or reaching sales numbers. The mean deal
value for the 500 transactions that did not involve milestone payments was $215.36 ± 528.47MM
as compared to the 172 transaction that involved milestone payments was $216.39 ± 661.92MM. -
There was no statistical significant difference in deal value associated with the presence or absence
of milestone payments. Furthermore, there was no significant difference in deal values with or
without earn out for companies as a function of the size of the acquirer. However, there was a
positive correlation between market cap (size of acquirer) and the use of earn out terms in the deal.
The presence of earn outs in the deal had no significant effect on the 30 day returns of the acquirer.
However, there was a positive correlation between mean returns at 30 days and the presence of
earn outs in the M&A transaction. Examining the use of earn out terms in different industry
sectors, deal value was shown to be significantly different in two sectors: Diagnostic Imaging
Equipment and Neurology Devices (p<0.05). No significant differences in deal value were
observed in any of the other industry sectors with respect to having earn outs present in the M&A
transaction terms (p>0.05).
Deal Value Model
Further examination of factors that influence deal value was undertaken using multivariable
regression analysis. The OLS Regression model uses Log (Deal Value) as the dependent value and
Date (Year), Earn outs, Log(Target Sales), Log(Acquirer Sales), Log (Acquirer Market Cap),
Regulatory approval, Multiple regulatory approvals, Financing (cash, stock, debt), Venture
backing, and target public or private as the independent values, Table XVII.
Log(Target sales), Log(Acquirer Market Cap), and if a company has been venture backed were
shown to be statistically significant at 5% levels with Log(Deal Value). The OLS regression model
had a R^2 value of 0.69 with an adjusted R^2 value of 0.65. Figure 14 shows a plot of the
Log(Deal Value) of actual deals plotted against Log(Deal Value) predicted with the model.
Table XVII: Deal value as a function of multiple factors. The OLS Regression model uses Log
(Deal Value) as the dependent value and Date (Year), Earn outs, Log(Target Sales), Log(Acquirer
Sales), Log (Acquirer Market Cap), Regulatory approval, Multiple regulatory approvals, Financing
(cash, stock, debt), Venture backing, and target public or private as the independent values.
Term Estimate Std Error
Intercept 16.2451* 33.5156
Date (Year) -0.0079 0.0167
Earn out?[N] -0.0283 0.0556
Log (Target sales) 0.7253* 0.0673
Log (Acquirer Sales) -0.0454 0.0886
Log (Market Cap) 0.2268* 0.0864
Regulatory Approval? [N] 0.0099 0.0806
Multiple Regulatory Approvals? [N] 0.0587 0.0726
Cash? [N] 0.0018 0.0769
Stock? [N] -0.0499 0.0689
Debt? [N] 0.0302 0.0692
Venture backed? [N] -0.1187* 0.0466
Target Private? [N] -0.0449 0.0496
*Statistical significance at 5%
Note: Log(Deal Value) = b + m*y + c(i)*x(i); where c(i) is the coefficient, x(i) is the corresponding value;
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Figure 14: Graphical representation of Log(Deal Value) Actual values plotted against Log(Deal
Value) Predicted values.
Chronological Order of Acquisition - Example Cases
Entering new markets has inherent risks associated with unknown revenue potential due to a
number of factors (i.e. immature markets, regulatory or reimbursement issues). However, once
markets develop target companies with large market share may experience larger merger and
acquisition deal values as compared to target companies that follow. Additionally, because of the
rapid innovation in the Medical Device Industry new markets can be highly competitive leading to
acquirer behavior that may drive deal value higher in industry sectors that do not have technology
solutions or competition that has captured significant market share. In our work, we selected four
different industry sectors to compare direct technology target companies that have either IPOed or
IPOed and were acquired or were acquired through and M&A transaction, Table XVIII-XXI.
Five Cardiovascular Device companies, seven Vascular Device companies, five Neurology Device
companies, and ten Orthopaedic Device companies were examined. A linear regression model
using Log(Deal value) as the dependent variable and Chronological Order of Transaction as the
independent variable were performed in each individual industry sector, Fig. 15.
Transaction deal value was shown to be positively correlated with the chronology of the deals in
the Cardiovascular Device (Atrial Fibrillation Device Case) and the Neurology Device
(Neurostimulation Device Case). Transaction deal values were shown to be negatively correlated
with chronology of the deals in the Orthopaedic Device and Equipment (Spine Market Case) and
the Vascular Device (Femoral Closure Case). Only the Vascular Device Case linear regression
model showed statistical significant relationship between rank and deal value at a 5% level. No
statistically significant relationships were found in the other three case studies. Furthermore, no
significant differences were found between the mean deal values for the firms that had an IPO or
M&A transaction.
Cardiac Devices - Atrial Fibrillation Case
Atrial fibrillation remains the most common cardiac arrhythmia which occurs when the atrial
chambers of the heart no longer contract synchronously, leading to a condition where blood is not
fully pumped out of the atria. The largest risk associated with atrial fibrillation is stroke (due to
clots that form as a result of the blood remaining in the atria). It is estimated that over 2.3 million
American adults have atrial fibrillation with over 150k new cases per year. These numbers are
expected to increase over two fold by 2050. The total AFib ablation market is attractive because it
is estimated to have a market size of greater than $5 billion dollars. There are no less than 20
companies developing treatment technologies for the treatment of AFib using both surgical and
catheter based treatments which attempt to duplicate the clinical results of the surgical Cox-Maze
procedure which has shown tremendous efficacy in treating AFib. Unfortunately, the surgical Cox-
Maze procedure is both invasive and technically challenging for most surgeons. In response to the
clinical demand for a technological solution that was less invasive, several medical device
companies formed that use ablation methods to mimic the Cox-Maze surgical procedure. Several
AFib companies either were acquired or IPOed between 1996 and 2006, Table XVIII. A positive
linear regression is shown for deal value as a function of chronological order of exit for target
companies in the Atrial Fibrillation space, Fig. 15. We believe that the correlation with increased
deal value is associated with an immature market without a therapeutic solution that treats the
clinical problem of atrial fibrillation. The market immaturity is associated with an incomplete
understanding of the causes of atrial fibrillation and can also be associated with deficiencies in the
current technologies (i.e. inability to create continuous transmural lesions set on the atrial that can
effectively treat the condition). In addition, the development of more minimally invasive
technologies expands the use of the technology and enables other specialties (i.e. interventional
cardiology) to treat AFib. Moreover, alternative treatments (i.e. pharmaceutical treatments) are
found to be ineffective in up to 50% of the patients after 1 year and 85% of patients at two years.
To date, there has been no US approval for a device indicated for the treatment of AFib. All
devices are labeled for soft tissue coagulation. The complex nature of AFib makes it difficult to
see one therapeutic treatment that will be effective across a broad population. Interestingly, the
soft tissue coagulation labeling is regulated under 510(k), making approval of devices much easier
than what is traditionally observed for cardiac treatment devices. A company that obtains labeling
for the treatment of AFib through a PMA approval process may command significant value. The
lack of an effective therapeutic treatment with a large potential market ($5B) fuels the M&A
environment for companies to invest in new promising technologies that may provide the
therapeutic treatment for AFib. Each of the large companies have made strategic acquisitions in
this space (Boston Scientific acquired EP Technologies, Guidant acquired AFx, St. Jude acquired
EpiCor (in addition to the AFib technology they also acquired mapping and navigation technology
through acquisition of Endocardial Solutions for $273MM), AtriCure and Cardima (Catheter
based) IPOed). The data suggests that companies are willing to make strategic acquisitions
because the clinical solution has not been optimized, making it a favorable exit potential for the
next technologies. Innovation is required in this sector to address the clinical need. For example,
improvement would include better mapping and navigation technologies, better ablation probes
that make complete transmural continuous lesion sets, and tools to allow for more minimally
invasive approaches to treat AFib conditions.
Table XVIII: Deal Value as a Function of Industry Sector and Chronological Order of M&A or
IPO Transaction in Cardiovascular Device-Atrial Fibrillation Company Example
Industry Sector Target M&A or Chronological Order of Deal Value
Name IPO Transaction ($MM)
Cardiovascular Devices - 1 56.54
Atrial Fibrillation Cardima Inc. IPO
Cardiovascular Devices - 2
Atrial Fibrillation Atrionix Inc. M&A 62.80
Cardiovascular Devices - EpiCor 3
Atrial Fibrillation Medical, Inc. M&A 200.00
Cardiovascular Devices - 4
Atrial Fibrillation AFx M&A 45.00
Cardiovascular Devices - 5 142.82
Atrial Fibrillation AtriCure Inc. IPO
Vascular Devices - Femoral Closure Case
There are well over 3 million catheter based interventions (i.e. angioplasty, stenting) that are
performed each year. With the increase in the number of catheter based interventions there was
instant recognition that manual compression to control bleeding at the femoral artery intervention
site was not sufficient. Specifically, the follow up care required for patients included observation
for periods up to 24 hours post procedure. Accordingly, many companies recognized that the
number of interventions was only likely to grow, so better methods to close the femoral artery
puncture site was required. The femoral closure market is estimated to be a $1B market. First
generation devices (i.e. VasoSeal by Datascope) were difficult to use, expensive, and limited
efficacy hampered the rapid adoption. Interestingly, because the reimbursement code at the time
required over night stays, hospitals did not have incentives to use the more expensive devices.
However, the next generation devices which entered the market between 1996 and 2006 included
Angioseal (TKN/St. Jude), Perclose (Abbott), and Vascular Solutions found increased adoption and
clinical success because of easy of use and clinical efficacy, Table XIX. In this work we show a
negative correlation between deal value and chronological order of acquisition, Fig. 15. This
suggests that subsequent acquisitions in this market will have less favorable deal values and terms.
The rationale for this environment is that the femoral closure market is mature in that it has well
defined clinical parameters/requirements and the product innovations are now incremental
improvements. For example, successful hemostasis is already between 95-98%, time to hemostasis
<2-4 minutes, and there are few complications (<2%). Drivers for innovations in this sector
include the expiration of current intellectual property protection, improving the ease of use,
changing the closure methods (i.e. leaving no implant behind) to address the potential for repeat
interventions at the same site, addressing the need to close larger access ports due to the use of
larger interventional devices (i.e. AAA or percutaneous valve devices), and to address the
complexity/diversity of patients (i.e. diabetic, obesity). The challenge for new technologies will be
market share, the low complication rates, and the PMA approval process (3-5 years) required to
approve new technologies. Accordingly, deal values in this industry segment are not expected to
grow but will continue to decrease unless significant innovations are developed that enable new
therapeutic treatments via interventional access.
Table XIX: Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Vascular Devices-Femoral Closure Comrany Example
Industry Sector Target Name M&A or Chronological Order of Deal Value
IPO Transaction ($MM)
Vascular Devices -
Femoral Closure TKN - Angioseal M&A 1 167.00
Vascular Devices -
Femoral Closure Perclose M&A 2 680.00
Vascular Devices - Vascular Solutions 3 105.18
Femoral Closure Inc IPO
Vascular Devices - Integrated Vascular
Femoral Closure Systems Inc. M&A 4 65.00
Vascular Devices - X-Site Medical -
Femoral Closure VasoSeal M&A 5 13.60
Vascular Devices -
Femoral Closure Angiolink M&A 6 45.00
Vascular Devices -
Femoral Closure Ensure Medical M&A 7 54.00
Neurology Devices - Neurostimulation Case
Neurostimulators can be described by a broad range of devices that include: deep brain stimulators
(DBS), vagus nerve stimulators (VNS), gastric stimulators, sacral nerve stimulators, and spinal
cord stimulators (SCS). These stimulators have the potential for treating a broad range of
conditions such as chronic pain, obesity, depression, and epileptic tremors by modulating the brain
and neural functions using electrical stimulation. One of the attractive aspects of neurostimulators
is that unlike pharmaceutical therapeutics, neurostimulators likely are considerably less risky (i.e.
less side effects). In 2006 the neurostimulator market was almost $630MM in the US and expected
continue to grow by 20% each year for the next 5+ years. The major market players are Medtronic,
Advanced Neuromodulation Systems, and Cyberonics with Advanced Bionics (acquired by Boston
Scientific) and Northstar Neurosciences are strong competitors. The large variety of potential
applications and the potential growth prospects make neurostimulation a very attractive market.
Each of these companies has multiple indications in different phases of FDA approval. For
example, in 2004 Cyberonics at one point had one approval (Epilepsy) and four other indications in
different phases of development (Depression, Anxiety, Alzheimer's disease, and Migraine
Headache). The uncertainty in the efficacy of the treatment of these devices particularly for the
breadth of application for such a broad range of disease and the rapid technology developments
such as that shown by Neuropace, demonstrate the potential for companies to enter this market. In
fact, each of the large device companies made early minor investments in several of these
companies (i.e. Boston Scientific and St. Jude Medical both made equity purchase in Cyberonics).
As companies research the possible applications of their neurostimulators and new markets emerge
the value of emerging neurostimulator companies will continue to grow. Table XX and Fig. 15
show the chronological rise in deal value for each of these M&A transactions. A positive
correlation between deal value and acquisition position was shown. In this industry segment the
immaturity of the market is obvious as companies continue research and develop applications
through clinical trials for the treatment of no less than 20 different disease indications. As new
companies emerge with advanced platform technologies that target specific disease indications,
deal values are likely to continue growing as the neurostimulation market expands and large
companies jockey to enter new markets and gain substantial market share. However, the challenge
companies face entering this market is the large capital requirements due to the need for the large
number of clinical trials required to demonstrate efficacy.
Industry Sector Target Name M&A or Chronological Order Deal Value
IPO of Transaction ($MM)
Neurology Devices -
Neurostimulation Advanced Bionics M&A 1 740.00
Neurology Devices -
Neurostimulation Cyberonics Inc. M&A/IPO 2 49.53
Neurology Devices -
Neurostimulation Transneuronix Inc. M&A 3 260.00
Advanced
Neurology Devices - Neuromodulation
Neurostimulation Systems M&A 4 1,300.00
Neurology Devices - Northstar Neurosciences, 5 346.20
Neurostimulation Inc. IPO
Orthopaedic Devices and Equipment - Spine Market Case
Mergers and Acquisitions in the Spine Market were almost 50% of the total deal values in the
Medical device industry ($4.4B/$9B). This industry segment continues to have rapid innovation
with spinal implants (i.e. dynamic stabilizers, plates, and screws), fusion technologies, and artificial
disc replacement technologies. Furthermore, rapid advancements in the Spine Market have lead to
the development of more minimally invasive technologies. This market is maturing as larger
companies are making acquisitions to fill product lines and optimize sales and distribution
channels. The M&A transactions in the Orthopaedic Device and Equipment sector are on average
one of the highest in the Medical Device Industry, Table XXI. However, we found a negative
correlation with deal values and chronological order of acquisition, Fig. 15. Moreover, we found
that in this sector larger companies utilize earn outs increasingly more in the deal transactions. For
example, acquisitions in this market sector have different deal structures based on earn outs (i.e.
Synthes purchase of Spine Solutions, J&J purchase of Link Spine) that constitute 50%+ of the
entire potential deal value.
Unlike other industry sectors, the orthopaedic spine market has undergone consolidation between
1996 and 2006. Many of the acquisitions have been made to gain market share (i.e. Zimmer
acquiring Centerpulse, J&J acquiring Depuy, Abbott acquiring Spinal Concepts). Additionally,
deal transaction values tend to be based on OUS approvals with US approvals pending or FDA
clinical studies in progress. Accordingly, without demonstration of target sales, we show that deal
values are significantly less than M&A transactions for targets with sales.
Table XX: Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Neurology Devices - Neurostimulation Com
pany 
E 
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Other challenges include reimbursement issues in Spine. For example, third party payers
(insurance companies) are interested in reimbursing for procedures that demonstrate that there is an
improvement of net health benefit and that it is equal to or better than current technologies/options.
Reimbursement for artificial disc replacement, for example Charite artificial disc (only approved
disc 2006), has been difficult. Initially The Centers for Medicare and Medicaid Services (CMS)
limited reimbursement to approximately 50% of the cost of the device ($11,600). Considering
most private insurers follow CMS's lead this was the general guideline for third party payers.
However, in February 2006, CMS issued a proposed decision memo on lumbar artificial disc
replacements: "The Centers for Medicare and Medicaid Services (CMS) is seeking public
comment on the proposed determination that the evidence is not adequate to conclude that lumbar
artificial disc replacement with the Charite lumbar artificial disc is reasonable and necessary.
Therefore, we propose to issue a national non-coverage determination." This new development
largely impacts how artificial disc replacement will challenge spinal fusion technologies. Without
reimbursement, adoption and use by physicians and hospitals will be limited, if not impossible, to
implement.
Although there have been significant innovations in the spine market with the development of
minimally invasive treatments (i.e. Kyphon for the treatment of vertebral fractures, Centerpulse
with dynamic stabilization, and St. Francis with spinal spacer), the Spine Market is mature.
Specifically, there are well defined markets with companies want to fill product line gaps and
companies consolidating to optimize sales and distribution lines. The large companies are fighting
for market share and although there are many clinical problems in spine, technological solutions
are become more difficult to discover and implement clinically. As a result, until technological
solutions with substantiated clinical benefit for intervertebral disc replacement or reduction in
lower back pain are found, the deal values in spine will continue to decline.
These results suggest that that in industry sectors such as Vascular Devices (Femoral Closure) and
Orthopaedic Devices and Equipment (Spine), the progressive acquisition of technologies and
accordingly maturity of market with solutions that address the clinical unmet need, the deal value is
negatively correlated with chronological order of acquisition. Furthermore, in these mature
markets, leap frog behavior can occur among industry leaders, however the ability to take large
market share or be a first mover/innovator has been diminished in value. Product innovation is
incremental with the clinical problems well defined in these sectors. Conversely, in industry
segments such as Cardiovascular Devices (Atrial Fibrillation) and Neurology Devices
(Neurostimulation) are shown to have positive correlation of deal value with chronological order of
acquisition. In these sectors, a firm understanding of the clinical problem and appropriate
procedure/technological solution has not been developed. These sectors continue to be expanding
markets but have very high clinical and regulatory burdens. This suggests that these markets are
relatively immature and product solutions that address the clinical unmet need are not sufficient.
Table XXI:Deal Value as a Function of Industry Sector and Chronological Order of M&A or IPO
Transaction in Orthopaedic Devices - Spine Technology Company Example
Industry Sector Target Name M&A or Chronological Order of Deal Value
IPO Transaction ($MM)
Orthopaedic Devices - Spine
Technologies Spine-Tech M&A 1 601.89
Orthopaedic Devices - Spine
Technologies Depuy M&A 2 3,500.00
Orthopaedic Devices - Spine
Technologies Kyphon IPO 3 534.67
Orthopaedic Devices - Spine Spinal Dynamics
Technologies Corporation M&A 4 269.50
Orthopaedic Devices - Spine
Technologies Spinal Solutions M&A 5 175.00
Orthopaedic Devices - Spine
Technologies Link Spine Group M&A 6 325.00
Orthopaedic Devices - Spine
Technologies Centerpulse AG M&A 7 1,999.06
Orthopaedic Devices - Spine
Technologies Spinal Concepts Inc. M&A 8 170.00
Orthopaedic Devices - Spine
Technologies SpineCore M&A 9 120.00
Orthopaedic Devices - Spine
Technologies Spine Next M&A 10 60.00
Cardiovascular Devices
Atrial Fibrillation
1 2 3 4 5 6
Rank
Orthopaedic Devices and Equipment
Spine
0 2 4 6 8 10
Vascular Devices
Femoral Closure
1 2 3 4 5 6 7
Rank
Neurology Devices
Neurostimulation
0
0
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Figure 15: Graphical representation of linear regression of Log(Deal Value) versus order of
transaction for (a) Cardiovascular Devices, (b) Vascular Devices, (c) Orthopaedic Devices and
Equipment, and (d) Neurology Devices.
0
0
0
0o
y = 1.73 + 0.07x = 0.14
S I II I J
O
O
O'0 O
0
O
.... y = 2.59- 0.17x R - 0.48
C i
O O""" -
O O '..
O"O
y. = 3.19- 0.11x = 0.41I 0 0 0o-
o0
-y~~y 3.19-O~lx R2=O.41
I
Chapter 5: Summary
In this work, specific internal and external company factors that effect Merger and Acquisition
transaction deal values were examined to provide a reasonable framework to explain how value is
created and captured by the target and acquiring firms in the Medical Device Industry. M&A
occurs for a variety of reasons that include attempts to improve efficiencies through economies of
scale and scope, attempts to reinvigorate product portfolios, attempts to enter new markets to drive
growth, and/or attempts to diversity holdings and limit volatility of markets. Recent trends have
shown that M&A activity by large cap companies has declined while mid cap companies appear to
be filling the gap that has emerged. It has been suggested that the weakened stock value of these
large cap companies along with more internal development of technologies has led to this recent
trend. Whereas, the stronger performance of the mid cap companies has led to larger transactions
as they capitalize on their strong market performance in recent years. In this work, it was shown
that the dynamic consolidation that occurs because of the M&A transactions can result in different
behavior among smaller and larger acquiring firms with respect to transaction deal value and terms.
We expected that the value extracted by the target and acquiring firms can be recognized by
examining correlations and significant difference between transactions in the Medical Device
Industry between January 1996 to October 2006. In brief, the $250B+ Medical Device Industry is
the fastest growing life science industry segment with an annual growth rate of about 23% over the
past 10 years. The Medical Device Industry is expected to continue its growth for the foreseeable
future. Unlike other industries the medical device industry spends significant resources in R&D
(11.4% of sales in 2002). This is a rapidly evolving industry requires innovation in order to
maintain market position or acquire market position. This industry is regulated under provisions of
the FDA and influenced by reimbursement decisions made by CMS. As a result, the value of
target companies can be largely influenced by regulatory and reimbursement factors. The active
consolidation of companies has led to growth of larger and larger leading medical device
companies with diversified holdings.
In this work, we developed a database with Medical Device Industry M&A transactions that had
publicly known deal values during the period of January 1996 to October 2006. We found 674
M&A transactions and 113 IPO transactions that had disclosed deal value from variety of publicly
accessible electronic and printed data sources. Deal values ranged from 140K to $57B with the
average deal value of $215.6MM (excluding the $27B Guidant and $57B Gillette deals). The
number of M&A transactions increased from an average of 40 per year to 79 per year between the
years of 1996 to 2006.
Medical Device Industry is regulated by the FDA. Accordingly, a correlation between approvals
and target sales in the US is expected. Between 1996 and 2006 there were 14,143 PMAs
approved and 39,523 510(k) issued by the FDA. In this work, we found statistically significant
correlations between firms having regulatory approval, the type of approval (PMA, 510(k), none),
and whether firms had multiple approvals with M&A transaction deal value. Firms with regulatory
approval had significantly higher deal values than firms with no approvals recorded. Moreover,
firms with multiple regulatory approvals prior to acquisition had significantly higher deal values.
Reimbursement for Medical Device firm products is largely controlled by decision made by the
Center for Medicare and Medicaid Services (CMS). Using sales revenue as a proxy for favorable
reimbursement for the target firm product(s), we found that deal values were statistically larger for
target companies with demonstrated sales. Accordingly the M&A transaction deal value correlated
significantly with the size of reported sales revenue. In addition, there was a significant correlation
between deal value as a function of sales and year in Cardiovascular Devices, Diabetes Equipment,
Diagnostic Imaging, and Patient Monitoring Equipment sectors. Deal values were highly variable
among specific Medical Device Industry Sectors, Table V and VI. However, the higher deal values
appear to be associated in sectors that have comparatively high Compound Annual Growth Rates
(CAGR), which reasonably correlates with industry trends for 'hot markets' or 'emerging markets'.
Over 5000 venture capital based financing deals occurred between January 1996 and October 2006
in the Medical Device Industry and totaled over $32B. Influence of venture capital investments in
the Medical Device Industry can be representative of the value that is created. By using transaction
deal value size as a proxy measure for value created, we compared venture financing with deal
value. We showed that target firms with venture financing were shown to have significantly higher
returns as compared to firms that did not have venture capital financing. This suggests that firms
benefit from access to capital, management experience, and other resources provided by or access
through venture firms.
Having regulatory approval, favorable reimbursement, and financial as well as management
resources from venture capital groups provide value to the target firms and has been shown in our
work to increase the deal value. However, there are additional theories based on the current
literature that may explain the deal values associated with M&A transactions in the Medical Device
Industry.
Dong et al 2003 proposed an overvaluation hypothesis in general M&A transactions which states
that high valued acquirers (i.e. companies with overvalued stock) tend to acquire lower valued
companies [21]. Moreover, this hypothesis states that high valued acquirer generally do not
observe increase in value as a result of the transaction in terms of stock returns. Note: the use of
equity may be interpreted as a signal that the equity of the acquiring firm is overvalued (signaling
hypothesis) to investors. Our work on M&A transactions in the Medical Device Industry found
similar findings -- we did not find increased value in terms of stock returns for companies,
particularly those that may have been overvalued. Examining returns over a 360 day event
window, we did not find a correlation between stock returns and deal value. In addition, we did not
find significant differences between 360 day returns and Market Cap of the acquiring company.
Myers and Majluf in 1984 developed models analyzing the use of stock overvalued or undervalued
situations by managers [22]. Similarly, Baker and Wurgler in 2002 suggested that firms use equity
to time the market and use the overvalued stock by irrational investors to finance transactions [23].
The signal that may be sent to investors when issuing stock is that the stock is overvalued. In
contrast, Dittmar and Thakor in 2007 suggest that managers use equity when the transaction is
likely to be aligned with investor views of the potential upside of the transaction [24].
Accordingly, it was important to determine if differences in deals that involved stock, cash or debt
in the M&A transactions exists. A significant majority of the Medical Device Industry M&A
transactions 430/525 involved cash in the transaction. Of the remaining deals, 165 had stock
included and 52 of the deals involved debt.
Moeller et al. 2003 and 2004 demonstrated that small firms have positive return no matter how the
acquirer financed the acquisition [4, 25]. Conversely, larger firms have negative returns when
financed with equity. Managers who believe that their stock is overvalued may be willing to issue
stock or equity as part of the compensation. Conversely, when managers believe stock is
undervalued they tend to pay with cash. In our work, we demonstrated no significant difference in
deal value with the type of financing. However, equity based deals did have higher average deal
values as compared to cash based deals. Andrade et al in 2001 showed that a significant number
of mergers in the 1990's were financed in part with stock (70%) with 58% of the mergers entirely
financed with stock [5, 26]. Advantages of stock deals are tax advantages (this is important
because the target will expect compensation from the acquirer) and use of overvalued acquirer
stock (acquirers want to take advantage of high currency value of the stock). Disadvantages of
using stock as compensation in M&A transactions are that they usually take longer than cash
transactions and stock transactions tend to send negative signals that stock is overvalued. It is
generally believed that cash deals outperform stock deals because of informational issues and use
of stock can dilute the current shareholders and affect control of the firm. Additional upside (short
term) with stock transactions is the instant increase in earnings of the acquiring firm (assuming that
the target firm has earnings) for the year of acquisition. The result is the acquisition will lead to
higher earnings per share for the acquirer! Travlos (1987) showed that firms that use equity to pay
for transactions generally observe lower returns [27]. In contrast, Fuller et al (2002) found that the
use of equity was no different than cash and had no effect on announcement returns [28]. We
looked at 3 day event window returns for stock versus cash based transactions and found that the
resulting transaction deal value is a function of both announcement reaction to merger and stock or
cash use in the transaction. Our work showed that there was no statistical difference in the deal
values associated with cash and stock financing terms. However, use of stock is significantly
associated with Market Cap of the acquiring company. Market Cap of the acquiring company was
not associated with use of cash or debt. Deals that had debt terms associated with the deal were
shown to have higher deal values than deals that involve pure stock or pure cash in the transaction.
Demsetz and Lehn (1985) suggested that better value for acquisitions by smaller firms may be
observed because the managers have higher incentives/vested interest in the acquiring firms than
managers in larger acquiring firms [29]. By using acquirer Market Cap and acquirer Sales prior at
the time of M&A transaction as proxy measurements of the size of the acquiring firm we found that
there was no correlation between size of the firm and the observed returns of the acquirer at 30
days. This is surprising in the context of other work such as Roll (1986) who suggested that larger
firms overbid or pay more for acquisitions [30]. Accordingly, one would suspect that these larger
firms may have worse returns as compared to the smaller firms. There are several reasons larger
firms tend to overbid or pay more for acquisitions: (1) to guarantee competition of the transaction
and (2) managers of larger firms tend to 'empire build'. Furthermore, Jensen (1986) suggested that
empire building managers may suffer from something he labeled as the 'free cash flow hypothesis'
[31]. The free cash flow hypothesis states that managers tend to make acquisitions based on
increasing the shareholder payouts. Our work found that large Medical Device Market
Capitalization companies ($5B+) were shown to pay more for target companies than smaller
market capitalization companies. The 3 day event window and 30 day returns both show negative
correlations with deal value, suggesting that acquirer in the Medical Device Industry do not show
benefits based on market returns for the acquisitions. The over payment for target companies can
also be accounted for by the notion that acquiring companies want to be sure that another buyer
will not enter into the bidding of the target. In this work, we were not able to account for the
presence of multiple bidders in any transaction that may have affected the results. In general
bidding by multiple bidders are private transactions that are difficult to obtain data for analysis
such as that performed in this work.
Firms that had access to the IPO market prior to M&A transactions were shown to have
significantly higher deal values. However, access to the IPO market has become very difficult for
firms, less than 10% of the transactions per year are IPOs versus M&A as compared to 1996 when
almost equal number of IPOs occurred as did M&A with publicly available deal values.
Rationale for higher acquisition values for IPOed companies is that these companies tend to be
more mature acquisitions (sales revenues). In our work, the 30 day acquirer returns with companies
that IPOed prior to M&A showed no difference as compared to acquisitions of companies that had
not IPOed prior to M&A. This suggests that the stockholders of the acquiring firm do not benefit
immediately from these types of transactions. We observed a significant drop off in IPO versus
M&A in the Medical Device Industry with M&A being the primary exit for smaller medical device
companies. Furthermore, we did not observed correlation difference between Market Cap of the
acquirer and the returns observed for private versus public acquisitions.
In this work, we showed that the top Medical Device firms made a large number of acquisitions
between 1996 and 2006. A number of these acquisitions appear to be diversifying acquisitions that
enable the firms to enter new markets with higher margins and higher growth rate. In the near term
these acquisitions can be dilutive and result in decreases in stock performance at the announcement
dates. On the positive side, these diversifying acquisitions can lead to increases in momentum of
the near term business, reward the companies for doing well, and change the cyclic nature of a
specialized firm. However, this may also signal that the firms have exhausted their internal growth
opportunities. Some argue that diversifying acquisitions decrease value of the firm, while others
argue increased value [32]. The cost associated with diversification for the acquiring firm are not
insignificant and can include issues related to management and internal culture, and large
inefficiencies between divisions. However, benefits can include economies of scope (operations)
and complementary manufacturing and technology use in new industry opportunities. The success
of large Medical Device Company diversification will be largely determined by the competitive
environment between firms in the sectors, the ability of the firm to take advantage of the newly
acquired resources, and the ability to integrate the new firm into the acquiring firm. We show that
diversification of firms does not impact the 30 day returns and is not associated with the size of the
acquirer.
Other deal terms that have more recently been used is the use of earn outs in the deal. Acquirers
utilize earn out or milestone based terms in deals to address market and regulatory risks and/or
maintain target company employee incentives post-acquisition. Alternatively, this may also be a
mechanism for target firms to extract more value in the transaction if it deems itself as being
undervalued by the acquiring firm. We hypothesized that the relative risk of the acquisition should
be reflected by lower acquirer stock price performance as compared to deals that do not contain
earn out or milestone terms. In our analysis we found that 172 of the 672 transaction had
milestones associated with the transaction deal terms. We found no significant difference in deal
values between deal with and deals without earn outs. However, it must be noted that payments
associated with the achievement of milestones (in most cases terms undisclosed) could perhaps
raise the value of deals with earn out higher than those with out. Since we do not know the final
deal payments with earn outs, one can suppose that deal with earn out may indeed have higher deal
values. There was a positive correlation between market cap of acquirers and use of earn out.
This may suggest that larger acquirers favor incentive based compensation and sharing of risk post-
acquisition with the target company shareholders. The 30 day returns of acquirers with or without
earn outs was not significantly different, suggesting that it does not matter to the market who is
sharing the risk in a M&A transaction - no change in value of the transaction once a target firm has
been acquired or shifting of value from acquirer shareholder to target shareholder. Mergers
historically are shown to benefit the target shareholders, but generally don't add immediate benefit
to the acquirer shareholders. In fact, the acquirer shareholder essentially subsidizes the M&A
transaction [5].
Entering new markets has inherent risks associated with unknown revenue potential due to a
variety of factors (i.e. immature markets, regulatory or reimbursement issues). However, once
markets develop target companies with large market share may experience larger merger and
acquisition deal values as compared to target companies that follow. Additionally, first mover
advantage and demonstration of clinical benefit are strong ways to establish market share.
However, the innovation and rapid changes in the Medical Device Industry can result in rapid
uptake and valuation of technologies. Using four example cases, we briefly explored the
complexities involved in understanding transaction deal value in the Medical Device Industry
sectors. Markets that are in developing (i.e. strong market leader is not present because clinical
benefit is not established or an effective therapeutic device that has not emerged) will continue to
have increasing deal value as firms attempt to establish market share and or acquire the
breakthrough technology. We found that there were positive correlation of M&A or IPO
transaction value for companies in less mature markets where companies have opportunities to leap
frog other companies in market position and share. Conversely, there is negative correlation of
M&A or IPO transaction value for companies in more mature markets.
Future studies should include a deeper examination of the short term versus long term abnormal
gains of combined entities as a function of industry sector. In particular, it would be interested to
examine if consolidation in the medical device industry has a direct effect on the abnormal gains of
these companies and if there is a critical company size that is not affected by these transactions. In
addition, it would be interesting to examine the effect of diversifying acquisitions as compared to
non-diversifying acquisitions on the short and long term performance of both mid cap and large cap
companies. It was observed that several transactions occurred in 'waves' for a particular acquiring
company attempting to enter new markets. It would be interesting to understand the market
premium that a company may pay and the associated returns observed in the short and long term.
One can speculate that markets are efficient and that abnormal returns should not be expected
because the acquisition cost should balance the upside. However, in the dynamically changing
Medical Device Industry where rapid innovation occurs and market position leap frog behavior is
not uncommon, abnormal returns may be observed. In this work, we briefly explored four different
technology areas in different industry sectors to examine trends for M&A transaction value. Other
example technologies area that can be explored in the future can include: Cardiovascular Devices
- Stents (Bare Metal Stents and Drug Eluting Stents), Orthopaedic Devices - Sports Medicine,
Orthopaedic Devices - Dynamic Stabilizers (Spine), Cardiovascular Devices - Patent Foreman
Ovale (PFO) Closure, Diabetic Equipment - Blood Glucose Monitoring, Cardiac Devices - Mitral
Valve Repair, etc... Future studies may examine the impact of regulatory requirements (i.e.
financial cost and time) and reimbursement issues on the exit value of medical device companies in
individual technology sectors. Moreover, the influence of intellectual property and reported
clinical outcome studies of technologies for the specific therapy should be considered in the study.
This study was limited to M&A transactions. However, arrangements, both strategic and financing
(i.e. licensing or funding), are also made between medical device companies. These arrangements
can impact sales and distribution channels, provide access to complementary technologies, and
help avoid intellectual property disputes. Accordingly, deal values may be influenced by the
presence of 'arrangements' between competitor companies and should be examined.
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Appendix
Table XXII: M&A Trar sacti alue Data
Acquisition Date Target Name Acquiror Name Deal Value ($)
1/16/1996 Orthopedic Technology DePuy AcroMed Inc. $ 46,200,000
1/17/1996 Medisorb Technology International Alkermes $ 7,000,000
1/18/1996 Corvita Corp Pfizer Inc. $ 85,000,000
1/26/1996 Symbiosis Boston Scientific Corporation $ 153,000,000
1/30/1996 Daig Corporation St Jude Medical Inc. $ 427,000,000
2/10/1996 Tissue Tech Palomar Medical Tech $ 25,000,000
2/26/1996 Sterile Concepts Holding Maxxim Medical $ 89,000,000
3/11/1996 Infrasonics Nellcor Puritan Bennett $ 66,000,000
3/11/1996 Synectics Medical Medtronic Inc. $ 59,000,000
3/18/1996 Microtek Medical Isolyser Co $ 87,500,000
3/25/1996 Instent Medtronic Inc. $ 214,000,000
3/25/1996 Ortho Products Orthopedic Technology $ 1,300,000
4/1/1996 Unimar CooperSurgical Inc. $ 8,000,000
4/11/1996 MediSense Abbott Laboratories Inc. $ 876,000,000
4/23/1996 Block Medical I-Flow Corporation $ 17,000,000
4/23/1996 Aladan London International Group $ 69,500,000
4/23/1996 Insight Imaging System New Image Industries $ 2,400,000
5/3/1996 Mintec Boston Scientific Corporation $ 70,000,000
5/10/1996 Advanced Surgical Intervention Uromed $ 30,000,000
5/16/1996 Lens Express Summit Technology $ 32,000,000
5/28/1996 Deknatel Snowden Pencer Genzyme Corp $ 250,000,000
7/22/1996 Sutter OrthoLogic Corporation $ 25,000,000
9/10/1996 Aequitron Medical Nellcor Puritan Bennett $ 61,000,000
10/21/1996 Pacific Dunlap St Jude Medical Inc. $ 135,000,000
10/23/1996 Ventritex St Jude Medical Inc. $ 505,000,000
11/13/1996 Medex Furon $ 160,000,000
12/1/1996 CardioSystems Crown Casino Corp $ 45,000,000
12/3/1996 Klein Medical LifeQuest Medical $ 1,725,000
12/4/1996 Research Medical Baxter International Inc. $ 235,000,000
12/5/1996 Cordis - Neuroscience Elekta Ab $ 9,000,000
12/10/1996 Cardiotronics Ballard Medical Products $ 11,400,000
1/6/1997 Ealing Electro-Optics Ltd Coherent Inc. $ 9,500,000
1/9/1997 Ideas for Medicine Cryolife $ 10,500,000
1/20/1997 Target Therapeutics Boston Scientific Corporation $ 1,100,000,000
2/4/1997 Medicine Lodge Innovasive Devices $ 19,100,000
2/4/1997 United States Surgical
Progressive Angioplasty Systems Corporation $ 78,000,000
2/11/1997 Innotech Johnson & Johnson $ 123,750,000
2/15/1997 New Image Industries DENTSPLY International Inc. $ 11,400,000
2/19/1997 Luxar Corp ESC Medical Systems $ 80,000,000
3/3/1997 Landanger-Camus DePuy AcroMed Inc. $ 129,300,000
3/13/1997 Microsurge, Inc. UroHealth Systems Inc $ 38,000,000
3/14/1997 Marguest Medical Products Vital Signs Inc. $ 18,600,000
4/7/1997 Bieffe Medital's IV Therapy and
Irrigating Solutions Business Baxter International Inc. $ 185,000,000
4/21/1997 Imagyn Medical Urohealth Systems $ 65,000,000
5/6/1997 Vivra Incentive $ 1,515,000,000
5/7/1997 Neocardia Guidant Corporation $ 77,000,000
5/14/1997 EyeSys Technologies Premier Laser Systems $ 10,600,000
5/22/1997 Biopsys Medical Johnson & Johnson $ 290,000,000
6/1/1997 InBrand Tyco Healthcare Group LP $ 320,000,000
7/14/1997 Burdick SpaceLabs Medical $ 50,000,000
7/24/1997 Nellcor Puritan Bennett Mallinckrodt $ 1.900.000.000
9/4/1997 Tecnol Medical Products Kimberly-Clark Health Care $ 400,000,000
9/15/1997 Phoenix Medical Technologies London International Group $ 6,650,000
10/6/1997 EndoVascular Technologies Guidant Corporation $ 170,000,000
10/23/1997 American Home Products Bausch & Lomb Inc. $ 380,000,000
11/10/1997 Laser Industries ESC Medical Systems $ 270,000,000
11/26/1997 Linvatec Corp CONMED Corporation $ 370,000,000
12/2/1997 Staodyn Rehabilicare Inc. $ 23,000,000
12/9/1997 United States Surgical
ValleyLab Corporation $ 425,000,000
12/16/1997 Spine-Tech Sulzer Medica AG $ 601,886,550
12/22/1997 Sherwood-Davis & Geck Tyco Healthcare Group LP $ 1,770,000,000
1/1/1998 USCI Aniographic Systems Arterial Vascular Engineering $ 550,000,000
1/29/1998 Ohmeda's medical devices division Becton Dickinson & Company $ 452,000,000
2/9/1998 Osteometer MediTech AS OSI Systems Inc. $ 7,750,000
2/12/1998 Diasonics Vingmed Ultrasound GE Medical Systems $ 230,000,000
2/16/1998 Elbit GE Medical Systems $ 100,000,000
3/2/1998 Coburn Optical Industries Gerber Optical $ 63,000,000
3/20/1998 AcroMed DePuy AcroMed Inc. $ 325,000,000
3/26/1998 Orcolite BMC Industires $ 100,000,000
3/30/1998 Can-Am Care Selfcare $ 27,000,000
4/1/1998 GAC International DENTSPLY International Inc. $ 195,000,000
4/9/1998 Vitajet Bioject Medical Tech $ 140,000
4/13/1998 World Medical Manufacturing Corp Arterial Vascular Engineering $ 62,000,000
4/29/1998 Lukens Medical Medisys plc $ 19,400,000
5/8/1998 Elekta Nitinol Medical Tech $ 33,000,000
Metorex International Oy's security
5/10/1998 products OSI Systems Inc. $ 5,885,000
5/19/1998 Theratronics International MDS Inc $ 15,450,000
6/1/1998 EndoMatrix, Inc. CR Bard Inc. $ 15,000,000
6/1/1998 US Surgical Tyco Healthcare Group LP $ 3,300,000,000
6/16/1998 Schneider Worldwide Boston Scientific Corporation $ 2,100,000,000
6/29/1998 Physio-Control International Medtronic Inc. $ 538,000,000
7/13/1998 Avecor Cardiovascular Medtronic Inc. $ 91,000,000
7/21/1998 Howmedica Stryker Corporation $ 1,900,000,000
7/21/1998 Depuy Johnson & Johnson $ 3,500,000,000
7/29/1998 ATL Ultrasound Inc. Philips Medical Systems $ 800,000,000
8/3/1998 Imation Eastman Kodak Company $ 520,000,000
8/4/1998 InControl Guidant Corporation $ 135,000,000
8/4/1998 i-Stat Corporation Abbott Laboratories Inc. $ 22,700,000
9/2/1998 Siebe plc's North Safety Products
business Norcross Safety Products LLC $ 220,169,570
9/10/1998 American Medical Systems Warburg Pincus $ 130,000,000
9/14/1998 Elbit GE Medical PLC $ 275,000,000
9/18/1998 Marquette Medical Systems GE Medical Systems $ 808,000,000
9/21/1998 SulzerMedica-Electrophysiology Guidant Corporation $ 817,823,220
9/22/1998 Graphics Controls Corp Tyco Healthcare Group LP $ 460,000,000
9/29/1998 Radiance Medical Systems Cardiovascular Dynamics $ 7,200,000
10/5/1998 FemRx Johnson & Johnson $ 22,000,000
10/14/1998 Luther Medical Products Becton Dickinson & Company $ 16,000,000
10/22/1998 Cardiogenesis Corp Eclipse Surgical Tech $ 86,000,000
11/2/1998 Star Medical Technologies (Palomar
Medical) Coherent Inc. $ 60,000,000
11/2/1998 Sofamor Danek Group Medtronic Inc. $ 3,600,000,000
11/20/1998 Circon Corp Maxxim Medical $ 240,000,000
1 1/25/1998 Cobe CV Fiate SPA $ 267,000,000
11/30/1998 Arterial Vascular Engineering Medtronic Inc. $ 3,560,000,000
12/4/1998 Brimfield Precision MedSource Technologies Inc. $ 6,000,000
12/23/1998 Ballard Medical Products Kimberly-Clark Health Care $ 764,000,000
1/11/1999 Vereingte Dentalwerke GmbH DENTSPLY International Inc. $ 55,330,020
2/2/1999 Ost Developpement SA Osteotech $ 1,500,000
2/6/1999 TKN - Angioseal St Jude Medical Inc. $ 167,000,000
3/8/1999 ICS North America Sparta Surgical Corp $ 9,100,000
4/1/1999 S&N Brace and Support Systems Chase Capital Partners $ 200,000,000
4/6/1999 Biodynamic Technologies Encore Medical Corporation $ 4,250,000
4/29/1999 B&L Sunglasses Luxottica Group SPA $ 640,000,000
5/25/1999 Tyndale - Plains Hunter CardioTech International Inc. $ 1,080,000
6/3/1999 Uroquest Medical Chemfab Corp $ 29,000,000
7/8/1999 Perclose Abbott Laboratories Inc. $ 680,000,000
7/16/1999 Compex SA Rehabilicare Inc. $ 12,752,500
7/26/1999 Exogen Smith & Nephew plc $ 68,000,000
8/2/1999 Collagen Aesthetics Inamed $ 142,000,000
8/9/1999 OEC Medical Systems GE Medical Systems $ 458,000,000
8/23/1999 General Surgical Innovations Tyco Healthcare Group LP $ 104,000,000
8/26/1999 Mentor Xomed $ 21,000,000
8/27/1999 Xomed Surgical Products Medtronic Inc. $ 800,000,000
8/30/1999 Implant Innovations Biomet Inc. $ 175,000,000
8/30/1999 CardioThoracic Systems Guidant Corporation $ 313,000,000
9/1/1999 VGM Medical Systems Adac Lab $ 18,000,000
9/9/1999 Vascular Science St Jude Medical Inc. $ 80,000,000
9/15/1999 Ecton Acuson $ 23,000,000
9/23/1999 Medical Graphics Angeion Corp $ 16,300,000
10/1/1999 Biosearch Medical Products CR Bard Inc. $ 650,000
11/9/1999 Innovasive Devices DePuy AcroMed Inc. $ 85,000,000
11/23/1999 Elekta Medtronic Inc. $ 11,750,000
12/22/1999 Althin Medical Baxter International Inc. $ 130,000,000
1/4/2000 Vidamed inc Medtronic Inc. $ 12,031,000
Advanced Neuromodulation
1/12/2000 Hi-tronics Designs Inc. Systems Inc. $ 15,675,000
1/18/2000 Sonamed Escalon Medical Corporation $ 12,500,000
1/18/2000 Spinal Specialties Inc. I-Flow Corporation $ 1,500,000
1/18/2000 Integra LifeSciences Holdings
Clinical Neuro Systems Corporation $ 6,800,000
1/31/2000 Thermedics Detection Inc. Theragenics Corporation $ 14,564,640
1/31/2000 Thermedics Inc. Thermo Electron Corporation $ 98,680,000
2/1/2000 Safeskin Kimberly-Clark Health Care $ 680,500,000
2/14/2000 IR-Vision Inc. SurgiLight Inc. $ 3,200,000
2/24/2000 Inovec Inc. InVision Technologies Inc. $ 5,000,000
Ocular Sciences, Inc. (FKA: O.S.I
3/20/2000 Corporation) Wesley Jensen Vision Care $ 428,000,000
Chronimed Inc's diagnostic product
4/12/2000 unit Medisys plc $ 40,000,000
Credit Suisse First Boston
4/12/2000 Zyomyx, Inc. Corporation $ 32,600,000
4/12/2000 Mobile Surgical Technologies Inc. Trimedyne Inc. $ 1,000,000
MEDgenesis Inc.'s diagnostics
4/12/2000 business Medisys plc $ 39,975,000
Computerized Thermal
4/18/2000 Bales Scientific Inc. Imaging Inc. $ 11,000,000
5/6/2000 Laser Power Corporation II-VI Inc. $ 44,180,000
Advent International
5/24/2000 Stereotaxis Inc. Corporation $ 25,500,000
5/25/2000 Protocol Systems Welch Allyn Inc. $ 131,000,000
5/29/2000 Summit Autonomous Inc. Alcon/Nestle $ 893,000,000
6/1/2000 Image Guided Tech Stryker Corporation $ 12,000,000
6/2/2000 Lunar Corp GE Medical Systems $ 146,000,000
6/26/2000 Bergen Brunswig Medical Allegiance Corp $ 181,000,000
6/28/2000 Mallinckrodt Inc. Tyco Healthcare Group LP $ 4,200,000,000
6/30/2000 Novacor World Heart Corp. $ 58,000,000
7/7/2000 Cadent Medical Corporation Cardiac Science Inc. $ 22,500,000
7/19/2000 Darway Inc. DENTSPLY International Inc. $ 3,400,000
7/19/2000 Bentley cardiopulmonary Jostra $ 30,000,000
8/4/2000 Endosonics Jomed NV $ 205,000,000
8/5/2000 STC Technologies Inc. Epitope Inc. $ 260,000,000
8/15/2000 Trex Medical Hologic Inc. $ 55,000,000
8/23/2000 BioStar, Inc. MetaMorphix Inc. $ 28,900,000
8/30/2000 Acculase Inc. PhotoMedex Inc. $ 3,750,000
9/5/2000 THM Biomaterial Kensey Nash Corporation $ 11,100,000
Transfusion Technologies
9/5/2000 Corporation Haemonetics Corporation $ 30,000,000
9/7/2000 Life Technologies Inc. Invitrogen Corporation $ 400,000,000
9/11/2000 Lumisys Eastman Kodak Company $ 39,000,000
San Diego Swiss Machining Inc.'s
ultrasonic dental instrument tip
9/18/2000 business DENTSPLY International Inc. $ 7,250,000
9/21/2000 Benecor Heart Systems ABIOMED Inc. $ 3,100,000
9/26/2000 Carl Zeiss - Woehlk Contact Lens Bausch & Lomb $ 26,200,000
9/26/2000 Woehlk Contact Lens GmbH Bausch & Lomb Inc. $ 26,200,000
9/26/2000 Biolectron Inc. EBI LP $ 90,000,000
Acuson Siemens Medical Solutions
9/27/2000 USA Inc. $ 700,000,000
American Securities Capital
10/1/2000 Miltex Instrument Company Inc. Partners LP $ 70,000,000
10/2/2000 EDAP TMS SA's prostratron
business Urologix Inc. $ 20,000,000
10/3/2000 Thermo Cardiosystems Thoratec Laboratories $ 695,000,000
10/4/2000 InnerDyne Inc. Tyco Healthcare Group LP $ 180,000,000
10/4/2000 Inverness Medical Innovations
Integ Inc. Inc. $ 7,180,000
10/18/2000 MedaSonics Inc. Cooper Companies Inc., The $ 7,100,000
10/19/2000 Percusurge, Inc. (FKA: perQsurge) Medtronic Inc. $ 225,000,000
10/31/2000 Neomorphic Inc. Affymetrix Inc. $ 86,884,000
11/1/2000 Lectec Tyco Healthcare Group LP $ 7,250,000
11/1/2000 Cardiotech International Nervation $ 7,540,000
11/2/2000 Core Vent Corp Sulzer Medica AG $ 100,000,000
11/13/2000 Beliersdorf AG Smith & Nephew plc $ 43,570,000
11/13/2000 AdacLab Philips Medical Systems $ 426,000,000
11/13/2000 S&N Product Biersdorf AG $ 120,500,000
Agilent Technologies' Healthcare
11/17/2000 Solutions Group Philips Medical Systems $ 1,700,000,000
Imagyn Medical Technologies Inc's
11/20/2000 Disposable Surgical Instrument Unit CONMED Corporation $ 8,000,000
11/21/2000 IVAX Diagnostics Inc. b2bstores.com $ 37,600,000
Biocare Biotecnogie fur die
12/1/2000 Therapie GMBH Modex Therapeutics $ 1,000,000
12/6/2000 NEN Life Sciences Inc. PerkinElmer Inc. $ 400,000,000
Inhale Therapeutic Systems
12/21/2000 Bradford Particle Design Plc Inc. $ 201,200,690
12/27/2000 Atrionix Inc. Johnson & Johnson $ 62,800,000
Medicomp Inc.; Telemedical United Therapeutics
12/28/2000 Procedures LLC Corporation $ 11,800,000
12/28/2000 Friadent GmbH DENTSPLY International Inc. $ 104,539,230
IntraTherapeutics, Inc. (FKA:
1/5/2001 Cardia Catheter Company) Sulzer Medica AG $ 145,000,000
1/10/2001 Artema Medical AB Cardiac Science Inc. $ 20,000,000
AstraZeneca's dental anaesthetics
1/19/2001 unit DENTSPLY International Inc. $ 136,500,000
1/26/2001 Heartport Inc. Johnson & Johnson $ 81,000,000
Implantable Devices Limited Advanced Neuromodulation
2/1/2001 Partnership; ESOX Technology Systems Inc. $ 2,430,000
Holdings LLC
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2/28/2001
3/16/2001
3/23/2001
4/3/2001
4/20/2001
4/24/2001
4/25/2001
4/26/2001
5/2/2001
5/3/2001
5/3/2001
5/7/2001
5/9/2001
5/11/2001
5/22/2001
5/23/2001
5/30/2001
5/30/2001
5/30/2001
5/30/2001
5/30/2001
5/31/2001
5/31/2001
5/31/2001
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6/21/2001
6/29/2001
6/29/2001
7/2/2001
7/4/2001
7/5/2001
7/6/2001
7/12/2001
8/5/2001
8/27/2001
9/3/2001
ATL Ultrasound Inc's Ultrasound
supplies business
Optex Ophthalmologics Inc
Ideas for Medicine
Hemasure
Cardiofocus
Sanofi-Synthelado Purges PA
SurvivaLink
Interventional Technologies
LXN Corporation
Eastern Isotopes Inc.
Embolic Protection, Inc.
Coherent Medical Group
Quanam Medical Corporation
Ela medical
Asta Medica AG
DeMaria ElectroOptics Systems Inc.
Gesellschaft fiir medizinische
Sondentechnik mbH
PharmaNetics Inc.
MedAmicus
Focal Inc
Scott Technologies Inc
Satelec Medical
Catheter Innovations, Inc.
(FKA:BWM Medical, Inc.)
Somnus Med Tech
OrthoLogic Corp's Continuous
Passive Motion business
Alza
Shearwater Corporation
Inverness - diabetes
Degussa Dental GmbH & Co KG
MiniMed Inc
Medical Research Group
C.R. Bard, Inc.
Sterion/J&J
Minntech Corporation
American OsteoMedix Corp
Hawe Neos Holding SA
Imagyn MedTech
Cook Pharmaceutical Solutions
Cardiac Pathways, Inc.
North American Imaging Inc.;
Aspect Electronics Inc.
Accumed International Inc
Marconi Medical Systems
Breas Medical AB
SeraCare Inc.
NeuroSupplies Inc.
CMED Catheter and Disposables
Technology, Inc.
Medscand Medical AB
CeraMed Dental LLC
Colorado MEDtech Inc.
Bausch & Lomb Inc.
Vascutech Inc
Whatman PLC
Edwards Lifesciences
Corporation
Mentor Corporation
Cardiac Science Inc.
Boston Scientific Corporation
Inverness Medical Innovations
Inc.
Ion Beam Applications SA
Boston Scientific Corporation
ESC Medical Systems
Boston Scientific Corporation
Snia SPA
Baxter International Inc.
Coherent Inc.
Integra LifeSciences Holdings
Corporation
Bayer Corporation
Cooper Companies Inc., The
Genzyme Biosurgery
Tyco Healthcare Group LP
Integra LifeSciences Holdings
Corporation
Boston Scientific Corporation
Gyrus Group
OrthoRehab Inc.
Johnson & Johnson
Inhale Therapeutic Systems
Inc.
Johnson & Johnson
DENTSPLY International Inc.
Medtronic Inc.
Medtronic Inc.
Tyco Healthcare Group LP
Oxboro Medical
Cantel Medical Corporation
Interpore Cross International
Sybron Dental Specialties Inc.
CONMED Corporation
Baxter International Inc.
Boston Scientific Corporation
McDonough Medical Products
Corporation
Ampersand Medical
Philips Medical Systems
Vital Signs Inc.
Grupo Grifols SA
Integra LifeSciences Holdings
Corporation
CardioTech International Inc.
Cooper Companies Inc., The
DENTSPLY International Inc.
$ 4,300,000
$ 3,000,000
$ 5,600,000
$ 13,000,000
$ 4,000,000
$ 32,000,000
$ 71,000,000
$ 345,000,000
$ 28,290,000
$ 28,000,000
$ 75,000,000
$ 100,000,000
$ 375,000,000
$ 126,000,000
$ 470,000,000
$ 22,500,000
$ 2,300,000
$ 17,400,000
$ 4,700,000
$ 17,400,000
$ 400,000,000
$ 3,600,000
$ 50,000,000
$ 55,700,000
$ 16,500,000
$ 126,000,000
$ 191,000,000
$ 1,300,000,000
$ 529,314,460
$ 3,200,000,000
$ 420,000,000
$ 3,200,000,000
$ 2,700,000
$ 70,000,000
$ 26,200,000
$ 45,000,000
$ 29,300,000
$ 219,000,000
$ 115,000,000
$ 5,738,580
$ 6,000,000
$ 1,100,000,000
$ 35,000,000
$ 147,500,000
$ 4,300,000
$ 1,300,000
$ 12,000,000
$ 25,000,000
9/7/2001 EDAX Inc. AMETEK Inc. $ 37,000,000
9/24/2001 Imatron GE Medical Systems $ 200,000,000
9/30/2001 Nephros Therapeutics Inc. Becton Dickinson & Company $ 8,700,000
10/1/2001 Alpha Therapeutic Haemonetics Corporation $ 83,000,000
Seattle Orthopedic Group Inc.'s United States Manufacturing
10/10/2001 manufacturing assets Co. $ 20,000,000
10/18/2001 Pro-duct Health Cytyc Corporation $ 174,000,000
NMT Medical's Vena Cava Filter
10/19/2001 Business CR Bard Inc. $ 27,000,000
10/24/2001 Vysis Inc. Abbott Laboratories Inc. $ 355,000,000
11/1/2001 Songbird Hearing Inc. Texas Instruments Inc. $ 45,000,000
Moyco Technologies Inc.'s Dental Miltex Instrument Company
11/1/2001 Supplies business' assets Inc. $ 17,500,000
11/4/2001 Analog Modules Inc. Heico Corporation $ 15,600,000
Integra LifeSciences Holdings
11/8/2001 GMS MBH Corporation $ 2,300,000
12/3/2001 VitalCom Inc Data Critical Corporation $ 10,800,000
12/6/2001 VidaMed Inc Medtronic Inc. $ 326,000,000
12/12/2001 Biosonix Neoprobe $ 5,450,000
Fifth Dimension Information
12/13/2001 Systems Inc Haemonetics Corporation $ 10,000,000
12/18/2001 Novametrix Medical Systems Inc. Respironics Inc. $ 85,140,000
12/20/2001 Inverness Medical Innovations
Unipath Ltd Inc. $ 149,430,480
Endonetics, Inc. (FKA: Akos
12/21/2001 Biomedical, Inc.) Medtronic Inc. $ 67,000,000
Inverness Medical Innovations
12/21/2001 IVC Industries Inc. Inc. $ 5,625,000
12/31/2001 Sterling Medivations Inc. SpectRx Inc. $ 4,000,000
1/7/2002 Teramed Cordis/J&J $ 70,000,000
Japan-Based Cardiovascular Joint Edwards Lifesciences
1/10/2002 Venture Corporation $ 22,000,000
1/11/2002 Ancore Corporation OSI Systems Inc. $ 14,250,000
1/15/2002 Biocompatibles International Cooper Companies Inc., The $ 98,600,000
Austenal Inc's partial denture
1/18/2002 business DENTSPLY International Inc. $ 18,300,000
Abbott Laboratories Inc.'s hospital
products division's anaesthesia kits
1/30/2002 and trays business Smiths Group plc $ 26,000,000
2/11/2002 Radiance Medical Systems Endologix $ 28,300,000
2/14/2002 Oratec Interventions Smith & Nephew plc $ 310,000,000
2/21/2002 Timm Medical Technologies Inc. Endocare Inc. $ 33,630,000
2/27/2002 Fusion Medical Technologies, Inc Baxter International Inc. $ 157,000,000
2/28/2002 Norland Medical Systems Cooper Companies Inc., The $ 5,000,000
Wockhardt Life Sciences'
3/1/2002 intravenous fluids business Baxter International Inc. $ 24,900,000
3/9/2002 IntraTherapeutics Inc. EV3 $ 95,000,000
Biocompatibles International plc's
3/18/2002 cardiovascular stent business Abbott Laboratories Inc. $ 234,500,000
3/19/2002 DOME Imaging Systems, Inc. Planar Systems, Inc. $ 61,000,000
3/22/2002 Spacelabs Medical Inc. Instrumentarium Oyj $ 140,000,000
Smith & Nephew pci's
3/28/2002 Rehabilitation business AbilityOne Corporation $ 124,077,240
General Electric Capital
4/4/2002 POINT Biomedical Corporation Corporation $ 28,300,000
4/9/2002 Cycam Inc. MedSource Technologies Inc. $ 23,730,000
Horizon Medical Products Inc's
medical products distribution
4/9/2002 business Arrow International Inc. $ 13,400,000
4/9/2002 Becton Dickinson AorTech International $ 21,500,000
4/18/2002 LumaLite Inc. Consil Corp $ 2,203,110
5/1/2002 Angiosonics Inc.'s Acolysis
intravascular ultrasound business Vascular Solutions Inc $ 1,500,000
5/2/2002 ALl Technologies McKesson Corporation $ 305,000,000
5/7/2002 Smiths Group plc's urology products
and ostomy products businesses Mentor Corporation $ 10,719,530
5/14/2002 BEI Medical Systems Company Inc. Boston Scientific Corporation $ 95,000,000
5/20/2002 Avantec Vascular Corp. Goodman Co Ltd $ 165,000,000
5/21/2002 Ackrad Laboratories Inc. Cooper Companies Inc., The $ 12,000,000
5/29/2002 Cryomedical Sciences Endocare Inc. $ 4,200,000
5/31/2002 Fuji RC Co. Ltd Respironics Inc. $ 23,000,000
6/4/2002 Surgical Dynamics Stryker Corporation $ 135,000,000
6/24/2002 Enteric Medical Technologies, Inc. Boston Scientific Corporation $ 35,000,000
6/26/2002 MDS Varian Medical Systems Inc. $ 11,000,000
Virtek Vision International Inc.'s
6/28/2002 Biotech Instruments business Bio-Rad Laboratories Inc. $ 6,617,260
6/28/2002 Spinal Dynamics Corporation Medtronic-Sofamor Danek $ 269,500,000
7/18/2002 US Lithotripsy LP US Medical Development Inc. $ 6,800,000
7/31/2002 Dumex Medical Inc. Derma Sciences Inc. $ 3,760,000
8/1/2002 NMT Medical Inc.'s neurosciences Integra LifeSciences Holdings
division Corporation $ 5,400,000
8/1/2002 Integra LifeSciences Holdings
Signature Technologies Inc. Corporation $ 2,800,000
Inverness Medical Innovations
8/8/2002 Wampole Laboratories Inc. $ 70,000,000
US Medical Development Inc's
8/13/2002 prostate treatment business Endocare Inc. $ 11,200,000
9/1/2002 Sound ID Texas Instruments Inc. $ 12,500,000
9/3/2002 Dendron GMBH Micro Therapeutics Inc. $ 25,000,000
9/7/2002 Imagis Technologies Inc. OSI Systems Inc. $ 1,750,000
Inverness Medical Innovations
9/9/2002 Ostex International Inc. Inc. $ 30,400,000
9/12/2002 Molectron Detector Inc. Coherent Inc. $ 11,500,000
Rocky Mountain Prostate HealthTronics Surgical
9/16/2002 Thermotherapy LLC Services Inc. $ 1,900,000
9/17/2002 Getz Bros Co., Ltd St Jude Medical Inc. $ 230,000,000
9/24/2002 IsoTis BV Modex Therapeutics $ 41,700,000
9/25/2002 Surgical Laser Technologies, Inc. PhotoMedex Inc. $ 3,632,000
9/30/2002 Cohesion Technologies Inc. Angiotech Pharmaceuticals Inc. $ 42,000,000
10/4/2002 Vascutek Terumo Medical Corporation $ 170,000,000
10/10/2002 StemSource Inc. Macropore Biosurgery Inc. $ 5,976,000
10/17/2002 Electro Medical Equipment Viasys Healthcare Inc. $ 22,500,000
10/21/2002 Meridian Medical Technologies Inc. King Pharmaceuticals Inc. $ 247,800,000
Integra LifeSciences Holdings
10/22/2002 Padgett Instruments Inc. Corporation $ 9,700,000
Edwards Lifesciences
10/22/2002 Baxter (Japan) Corporation $ 22,000,000
10/28/2002 Gish Biomedical CardioTech International Inc. $ 7,200,000
10/30/2002 Bio-plexus ICU Medical Inc. $ 8,900,000
11/4/2002 Vertis Neuroscience Inc. TAT Capital Partners $ 37,000,000
11/5/2002 Advanced Neuromodulation
Micronet Medical Inc. Systems Inc. $ 5,733,000
11/5/2002 Bridge Medical Amerisource Bergen Corp $ 27,000,000
11/11/2002 Cardio Control Welch Allyn Inc. $ 19,000,000
11/21/2002 Diagnostic Imaging PSS World Medical $ 116,000,000
11/27/2002 Carbomedics and Mitroflow Snia SPA $ 116,000,000
12/2/2002 Gyrus Group ple's surgical drapes Microtek Medical Holdings
business Inc. $ 4,000,000
12/10/2002 Argomed ACMI $ 3,500,000
12/11/2002 Cardiac Intelligence Guidant Corporation $ 19,300,000
American Medical Systems
12/16/2002 CryoGen Inc. Holdings Inc. $ 40,000,000
12/17/2002 Instrumentarium Oyj GE Medical Systems $ 2,362,948,960
Quinton Cardiology Systems
12/23/2002 Spacelabs Burdick Inc. Inc. $ 20,400,000
1/6/2003 Del Mar Medical Systems Ferraris Group plc $ 10,000,000
1/7/2003 Neometrics Inc. Natus Medical Inc. $ 3,600,000
Genzyme Corporation's
1/7/2003 cardiothoracic devices business Teleflex Inc. $ 40,400,000
Abbott Laboratories Inc' rapid Inverness Medical Innovations
1/10/2003 diagnostics business Inc. $ 92,500,000
1/13/2003 Bionx Implants CONMED Corporation $ 47,000,000
1/14/2003 SciMed Viasys Healthcare Inc. $ 870,000,000
1/29/2003 Orquest DePuy AcroMed Inc. $ 85,000,000
2/6/2003 Spinal Solutions Synthes-Stratec $ 175,000,000
2/7/2003 Poly Implant Prostheses Heritage World $ 21,300,000
2/10/2003 Disetronic Holding AG Roche Holding AG $ 1,200,000,000
Jomed's Mitral Valve Repair System Edwards Lifesciences
2/18/2003 Corporation $ 20,000,000
2/27/2003 YXLON International X-Ray GmbH InVision Technologies Inc. $ 53,010,470
3/3/2003 Angiometrix Medical Ventures Corp $ 2,600,000
Genomic Instrumentation Services
3/3/2003 Inc. Genomic Solutions Inc. $ 8,100,000
3/4/2003 Sanatis GmbH Kyphon Inc. $ 4,300,000
3/4/2003 Intavent Orthofix International $ 20,450,000
3/7/2003 Computer Motion, Inc. Intuitive Surgical Inc. $ 66,200,000
3/7/2003 SpectRx-Bilichek Non Invasive Respironics Inc. $ 11,250,000
Diagnostic Products Corporation's
3/7/2003 PathoDx line of products Remel Inc $ 4,900,000
Unnamed company's electronics
3/10/2003 manufacturing business OSI Systems Inc. $ 4,400,000
3/10/2003 Neuromag Elekta Ab $ 4,400,000
3/11/2003 In Vivo Corp Intermagnetic General Corp $ 152,000,000
3/11/2003 X Technologies Guidant Corporation $ 200,000,000
3/12/2003 Shenzhen New Industries' 15
refractive laser centres LaserSight Inc. $ 6,000,000
Sun Medical Inc's pain management Advanced Neuromodulation
3/13/2003 business Systems Inc. $ 5,100,000
3/13/2003 Colorado MEDtech, Inc. KRG Capital Partners, LLC $ 62,500,000
Integra LifeSciences Holdings
3/18/2003 JARIT Surgical Instruments Corporation $ 44,500,000
3/21/2003 Bioabsorbable Vascular Solutions Guidant Corporation $ 16,000,000
4/3/2003 Medical Data Electronics In Vivo Corp $ 9,400,000
4/25/2003 Prism Enterprises Cooper Companies Inc., The $ 23,000,000
5/3/2003 EpiCor Medical, Inc. (FKA:
Epicardia, Inc.) St Jude Medical Inc. $ 200,000,000
5/6/2003 Link Spine Group DePuy AcroMed Inc. $ 325,000,000
5/12/2003 American Medical Tech. Biolase Tech. $ 5,400,000
Weston Medical's Intraject
5/13/2003 Technology assets Aradigm Corporation $ 2,000,000
5/13/2003 Sanomed Sonic Innovations $ 13,000,000
5/16/2003 BMR Neurotech Inc Compex Technologies Inc. $ 3,300,000
5/20/2003 Centerpulse AG Zimmer Holdings Inc. $ 1,999,063,740
5/27/2003 JOMED NV - Coronary division Abbott Laboratories Inc. $ 91,470,390
Edwards Lifesciences
6/1/2003 Vascular Architects Inc. Corporation $ 16,000,000
6/2/2003 Gensci Regeneration Sciences IsoTis $ 29,200,000
6/2/2003 Spinal Concepts Inc. Abbott Laboratories Inc. $ 170,000,000
6/3/2003 Medivance Inc's patient warming
business Kimberly-Clark Health Care $ 17,000,000
6/13/2003 Bionostics Inc Ferraris Group plc $ 31,000,000
6/30/2003 Genzyme Biosurgery Teleflex Inc. $ 40,400,000
6/30/2003 MindGuard Ltd Medtronic Inc. $ 15,000,000
7/11/2003 VSM MedTech Ltd FMR Corporation $ 12,987,300
Diametrics Medical Inc.'s International Technidyne
7/18/2003 intermittent testing business assets Corporation $ 5,750,000
7/22/2003 Biomec Medamicus $ 18,000,000
Mar Cor Services Inc.; Biolab
7/23/2003 Group, The Cantel Medical Corporation $16,300,000
Inverness Medical Innovations
7/31/2003 Applied Biotech Inc. Inc. $ 27,630,000
8/1/2003 Applied Optronics Cantel Medical Corporation $ 1,200,000
8/13/2003 Mathys Medical Synthes-Stytec $ 1,000,000,000
8/14/2003 Revivant Corp ZOLL Medical Corporation $ 15,000,000
8/15/2003 Siemens Getinge $ 17,000,000
8/18/2003 AbilityOne Corporation Patterson Dental Company Inc $ 575,000,000
8/19/2003 Mirada Solutions Ltd CTI Molecular Imaging Inc. $ 22,000,000
9/17/2003 Jouan SA Thermo Electron Corporation $ 132,000,000
9/26/2003 Integrated Vascular Systems Inc. Abbott Laboratories Inc. $ 65,000,000
10/2/2003 VirtualScopics LLC GE Medical Systems $ 3,800,000
10/9/2003 Orthologic-Bone Growth Bus DJ Orthopedics Inc. $ 93,000,000
10/13/2003 Zmed Varian Medical Systems Inc. $ 35,500,000
Endocare Inc.'s urodynamics and
10/17/2003 incontinence assets SRS Medical Systems Inc. $ 3,000,000
10/21/2003 Complient Corporation Cardiac Science Inc. $ 47,460,000
10/24/2003 Parallax (Medical Device Alliance) ArthroCare Corporation $ 28,000,000
Edwards Lifesciences
10/24/2003 Atritech Inc. Corporation $ 10,000,000
10/27/2003 NOMOS Corporation North American Scientific Inc. $ 56,000,000
10/28/2003 Integra LifeSciences Holdings
Spinal Specialties Inc. Corporation $ 6,000,000
10/28/2003 Avalon Medical Cooper Companies Inc., The $ 10,000,000
Maxxim Medical Inc's surgical and
10/28/2003 medical products assets Medline Industries Inc. $ 100,900,000
10/30/2003 Altiva Corporation Exactech Inc. $ 1,000,000
11/7/2003 Explorent Gyrus Group $ 6,270,000
11/8/2003 Ingenuity Systems Inc. Affymetrix Inc. $ 5,000,000
11/8/2003 TransVascular, Inc. Medtronic Inc. $ 60,000,000
11/11/2003 Medstone International Inc. Prime Medical Services Inc. $ 18,250,000
11/12/2003 Vertelink Group Medtronic Inc. $ 22,000,000
11/19/2003 BREG, Inc. Orthofix International $ 150,000,000
11/20/2003 Schwartz Electro-Optics' assets OSI Systems Inc. $ 1,500,000
11/24/2003 Implex Corp Zimmer Holdings Inc. $ 89,000,000
12/4/2003 STS Biopolymers Angiotech Pharmaceuticals Inc. $ 23,000,000
12/11/2003 Dentsply Gendex Danaher Corporation $ 102,500,000
12/15/2003 Drew Scientific Group plc Escalon Medical Corporation $ 8,333,330
Edwards Lifesciences
12/15/2003 Percutaneous Valve Technologies Corporation $ 125,000,000
12/15/2003 i-Stat Corporation Abbott Laboratories Inc. $ 392,000,000
12/18/2003 BioMer CV Biomet Inc. $ 300,000,000
12/22/2003 Vista Medica Tech Viking Systems $ 2,300,000
12/31/2003 Qualia Computing iCAD $ 31,850,000
1/5/2004 Spacelabs Medical Inc. OSI Systems Inc. $ 47,000,000
1/7/2004 Atto Bioscience Inc. Becton Dickinson & Company $ 25,000,000
1/12/2004 ProCyte Corporation PhotoMedex Inc. $ 23,570,000
1/13/2004 Therasense Inc. Abbott Laboratories Inc. $ 1,200,000,000
Kimberly-Clark Corporation's
1/14/2004 wound care assets Derma Sciences Inc. $ 2,600,000
1/20/2004 Moore Medical McKesson Corporation $ 38,300,000
1/22/2004 AFx Guidant Corporation $ 45,000,000
1/30/2004 MEMS USA Inc. (California) MEMS USA Inc. $ 19,544,220
2/3/2004 Milex Products Cooper Companies Inc., The $ 26,000,000
2/6/2004 Saf-T-Pak Inc. Cantel Medical Corporation $11,500,000
Viva Diagnostika - Diagnostische Inverness Medical Innovations
2/6/2004 Produkte GmbH Inc. $ 5,673,000
2/24/2004 Asterand Inc. Pharmagene plc $ 44,255,620
3/1/2004 Novacept, Inc. (FKA: Acuvasive) Cytyc Corporation $ 325,000,000
3/8/2004 Interpore Cross International (FKA:
Interpore International) Biomet Inc. $ 259,140,000
3/12/2004 Midland Medical Technology Smith & Nephew plc $ 121,000,000
Fisher Scientific International
3/17/2004 Apogent Technologies Inc. Inc. $ 3,630,000,000
CardioDynamics International
3/23/2004 Vermed Corporation $ 16,500,000
3/29/2004 Kaltenbach & Voight Danaher Corporation $ 429,000,000
4/3/2004 Optx Corporation Varian Medical Systems Inc. $ 18,000,000
4/15/2004 SSL International PLL Medlock Medical Holdings $ 99,700,000
4/21/2004 Pfizer's Opthalmology Advanced Medical Optics Inc. $ 450,000,000
4/21/2004 Circe Biomedical Arbios Systems $ 200,000
4/29/2004 Chrysalis BioTechnology Inc. OrthoLogic Corporation $ 34,500,000
Eagle-Picher Technologies LLC's
4/29/2004 scientific products division Apogent Technologies Inc. $ 23,000,000
Western Biomedical Technologies
5/3/2004 Ltd Respironics Inc. $ 5,500,000
BioSurface Engineering
5/8/2004 Technologies Inc. Boston Scientific Corporation $ 5,000,000
5/13/2004 Horizon Medical Rita Medical Systems $ 109,000,000
5/17/2004 Hudson Respiratory Care Inc. Teleflex Inc. $ 460,000,000
5/19/2004 Alaris Medical System Cardinal Health Inc. $ 2,000,000,000
5/25/2004 X-Site Medical - VasoSeal DataScope $ 13,600,000
6/1/2004 Advanced Bionics Boston Scientific Corporation $ 740,000,000
6/12/2004 Gambro Healthcare US Inc. DaVita Inc. $ 3,050,000,000
6/12/2004 Lantor (UK) Ltd WL Gore & Associates Inc. $ 9,718,170
6/14/2004 HealthTronics Surgical Services Inc. Prime Medical Services Inc. $ 250,000,000
American Medical Systems
6/15/2004 TherMatrx Inc. Holdings Inc. $ 250,000,000
Inverness Medical Innovations
6/16/2004 Advantage Diagnostics Corporation Inc. $ 4,110,000
6/18/2004 Concorde Microsystems Inc. CTI Molecular Imaging Inc. $ 41,000,000
7/1/2004 DHD Healthcare Smiths Group plc $ 55,000,000
7/6/2004 Acrorad Co., Ltd TeraRecon Inc. $ 6,748,850
American Medical Systems
7/15/2004 BSD Medical Holdings Inc. $ 40,000,000
7/19/2004 Regent Medical SSL International $ 310,000,000
7/21/2004 SpineCore Stryker Corporation $ 120,000,000
7/28/2004 Ocular Science Cooper Companies Inc., The $ 1,100,000,000
demedis GmbH; Euro Dental
8/1/2004 Holding GmbH Henry Schein Inc. $ 307,377,050
8/9/2004 Empi Inc. Encore Medical Corporation $ 362,000,000
8/10/2004 Irvine Biomedical St Jude Medical Inc. $ 60,000,000
CR Bard Inc's Endoscopic
Technologies division's certain
8/18/2004 assets CONMED Corporation $ 80,000,000
8/23/2004 Innova LifeSciences Corporation Sybron Dental Specialties Inc. $ 48,183,590
9/3/2004 Coalescent Surgical Medtronic Inc. $ 60,000,000
9/6/2004 Opus Medical ArthroCare Corporation $ 90,000,000
9/15/2004 Advanced Neuromodulation
Cyberonics Inc. Systems Inc. $ 49,525,000
9/21/2004 Atlantis Components Inc. Danaher Corporation $ 12,500,000
9/22/2004 Endocardial Solution St Jude Medical Inc. $ 273,000,000
9/29/2004 ev3's Percutaneous Mitral Valve Edwards Lifesciences
Repair Programme Corporation $ 15,000,000
10/11/2004 OEM Concepts Inc. Meridian Bioscience Inc. $ 8,300,000
10/11/2004 Magnex Scientific Varian Medical Systems Inc. $ 32,000,000
10/14/2004 Core Systems Inc. Implant Sciences Corporation $ 5,250,000
10/25/2004 Spine Next Abbott Laboratories Inc. $ 60,000,000
Gulfgate Equipment Inc.; Bott
10/27/2004 Equipment Company Inc. MEMS USA Inc. $ 2,300,000
Fisher Scientific International
11/2/2004 Oxoid Group Holdings Ltd Inc. $ 330,000,000
11/8/2004 ImTek Inc. CTI Molecular Imaging Inc. $ 3,750,000
11/8/2004 Sterion Inc's medical product
business Aspen Surgical Products Inc. $ 6,500,000
11/9/2004 Visx Inc. Advanced Medical Optics Inc. $ 1,260,000,000
Cosmed Group Inc.'s 5 medical
11/16/2004 device sterilisation locations Steris Corporation $73,000,000
11/17/2004 Angiolink Medtronic Inc. $ 45,000,000
11/18/2004 SSL International PLL Langer Inc $ 15,500,000
Integra LifeSciences Holdings
11/18/2004 Newdeal SA Corporation $ 51,081,330
12/1/2004 H6rnell International AB 3M Company $ 100,914,960
12/4/2004 Aspect Medical Systems Inc. Boston Scientific Corporation $ 7,970,000
12/6/2004 Medex Smiths Group plc $ 925,000,000
12/14/2004 Microline Inc. Pentax Corporation $ 49,000,000
12/16/2004 Cygnus Inc's certain assets Animas Corporation $ 10,000,000
12/16/2004 Advanced Stent Technologies Boston Scientific Corporation $ 120,000,000
Oxford Instruments pie's Medical
1/3/2005 business Viasys Healthcare Inc. $ 46,127,230
1/5/2005 ProRhythm Inc. St Jude Medical Inc. $ 125,000,000
Amplimedical SpA's orthopaedic
1/6/2005 division AMETEK Inc. $ 3,814,450
1/17/2005 Sigma Micro Informatique Conseil Varian Medical Systems Inc. $ 13,000,000
1/18/2005 OREX Computed Radiography Ltd Eastman Kodak Company $ 51,300,000
1/19/2005 InnoRx Inc. SurModics Inc. $ 38,636,000
Advanced Clinical Systems
International Pty Ltd's consumer Inverness Medical Innovations
1/24/2005 pregnancy test business Inc. $ 4,549,860
1/28/2005 Gillette Company, The Procter & Gamble Company $ 57,000,000,000
1/28/2005 Mission Medical Inc. Terumo Medical Corporation $ 18,000,000
1/31/2005 Medquest Products World Heart Corp. $ 9,300,000
2/3/2005 Osteoimplant Tech Encore Medical Corporation $ 14,500,000
Medcare Investment Fund Ill
2/3/2005 Refocus Group Inc. Ltd $ 7,000,000
2/6/2005 superDimension Ltd Pfizer Inc. $ 27,000,000
2/8/2005 Inverness Medical Innovations
Binax Inc. Inc. $ 55,836,000
2/9/2005 Proxima Therapeutics Cytyc Corporation $ 160,000,000
2/11/2005 Iolon Inc's assets Coherent Inc. $ 5,000,000
2/14/2005 Enable Medical Corporation AtriCure Inc. $ 7,000,000
2/14/2005 Verigen AG Genzyme Corp $ 10,000,000
2/15/2005 Velocimed, Inc. St Jude Medical Inc. $ 82,500,000
Ischemia Technologies, Inc. Inverness Medical Innovations
2/16/2005 Inc. $ 24,000,000
2/23/2005 eTrauma.com Corporation Stryker Corporation $ 50,000,000
2/28/2005 Hospira Inc's Salt Lake City
manufacturing facility ICU Medical Inc. $ 32,000,000
3/4/2005 Closure Medical Corporation Johnson & Johnson $ 387,747,000
3/8/2005 Crosstex International Inc. Cantel Medical Corporation $ 86,200,000
Inverness Medical Innovations
3/10/2005 Thermo BioStar Inc. Inc. $ 28,900,000
3/14/2005 Superior Medical Equipment LLC DJ Orthopedics Inc. $ 3,700,000
3/15/2005 MicroMed Technology, Inc. Viasys Healthcare Inc. $ 40,400,000
3/17/2005 Infusion Dynamics, Inc. ZOLL Medical Corporation $ 6,600,000
Siemens Medical Solutions
3/18/2005 CTI Molecular Imaging Inc. USA Inc. $ 966,780,000
3/29/2005 NITON LLC Thermo Electron Corporation $ 40,500,000
VisionCare Ophthalmic
4/1/2005 Technologies Inc. Boston Scientific Corporation $ 20,000,000
4/2/2005 SurgiCount Medical Inc. Franklin Capital Corporation $ 4,000,000
4/4/2005 Mini-Mitter Company Inc. Respironics Inc. $ 10,500,000
4/8/2005 Aureon Laboratories Pfizer Inc. $ 20,000,000
4/14/2005 Rubicon Medical Boston Scientific Corporation $ 71,700,000
4/20/2005 Health E Monitoring Inc. Quest Medical $ 1,000,000
4/25/2005 CP Medical Theragenics Corporation $ 25,400,000
4/27/2005 Impella ABIOMED Inc. $ 73,826,000
5/2/2005 Valley Forge Scientific
Synergetics Inc. Corporation $ 29,920,000
5/4/2005 Renal Care Group Fresenius AG $ 3,300,000,000
5/5/2005 Saime SA ResMed Inc. $ 108,216,940
Fisher Scientific International
5/8/2005 Cellomics Inc. Inc. $ 49,000,000
5/16/2005 Statcorp Inc CAS Medical Systems Inc. $ 4,200,000
5/16/2005 Pulmonetic Systems Viasys Healthcare Inc. $ 98,000,000
5/24/2005 ThermopeutiX Inc. SurModics Inc. $ 1,000,000
5/31/2005 ParAllele BioScience Inc. Affymetrix Inc. $ 120,800,000
Abbott Laboratories Inc's
Determine/DainaScreen rapid Inverness Medical Innovations
5/31/2005 diagnostic business Inc. $ 56,500,000
RSB Spine LLC's Cervical Plate
6/6/2005 Technology Assets NuVasive Inc. $ 14,500,000
American Medical Systems
6/6/2005 Ovion Holdings Inc. $10,000,000
Fortron Bio Science Inc.;
6/7/2005 BiosPacific Inc. R&D Systems Inc. $ 20,000,000
6/10/2005 Itamar Medical Ltd Medtronic Inc. $ 12,000,000
6/13/2005 Tuilaser AG Coherent Inc. $ 27,243,010
6/20/2005 Pelton & Crane Danaher Corporation $ 85,000,000
6/20/2005 Medcon Ltd McKesson Corporation $ 105,000,000
6/20/2005 Orgis Medical Corporation Boston Scientific Corporation $ 22,700,000
6/21/2005 Genaissance Pharmaceuticals Inc. Clinical Data Inc. $ 56,000,000
6/28/2005 Corautus Genetics Inc. Boston Scientific Corporation $ 7,980,000
6/29/2005 Transneuronix Inc. Medtronic Inc. $ 260,000,000
6/30/2005 Biophan Technologies Inc. Boston Scientific Corporation $ 5,000,000
7/1/2005 aMRIs GmbH iG Biophan Technologies Inc. $ 3,600,000
7/5/2005 West Pharmaceutical Services
Medimop Medical Projects Ltd Inc. $ 41,800,000
7/6/2005 Stentor Inc. Philips Medical Systems $ 280,000,000
7/14/2005 SightLine Technologies Ltd Boston Scientific Corporation $ 10,000,000
Appriva Medical, Inc. (FKA: MV
7/26/2005 Medical Devices, Inc.) EV3 $ 80,000,000
Micrus Endovascular
7/28/2005 VascularFX LLC Corporation $ 4,000,000
8/2/2005 General Orthodontic LLC Align Technology, Inc. $ 2,400,000
8/2/2005 Blease Medical Holdings Ltd OSI Systems Inc. $ 19,962,860
8/2/2005 HealthTronics Inc's Orthopaedic
Electrocorporeal Shockwave
Lithotripsy assets SanuWave Inc. $ 10,400,000
8/9/2005 Encore Medical Corporation's
orthopedics soft goods business DJ Orthopedics Inc. $ 10,000,000
8/12/2005 Aerogen Inc. Nektar Therapeutics $ 32,000,000
8/12/2005 MYOTECH LLC Biophan Technologies Inc. $ 10,408,000
Image-Guided Neurologics (FKA:
8/31/2005 IG3D Corp.) Medtronic Inc. $ 68,000,000
9/5/2005 BioniCare Medical Technologies Allen & Company Inc. $ 15,000,000
Tyco Healthcare Group LP's Integra LifeSciences Holdings
9/7/2005 Radionics Division Corporation $ 80,000,000
9/13/2005 Replication Medical Inc. Abbott Laboratories Inc. $ 15,000,000
9/13/2005 Biosil Ltd; Nagor Ltd MediCor Ltd $ 47,597,790
Thermo Electron Corporation's
Point of Care and Rapid Diagnostics Inverness Medical Innovations
9/19/2005 Business Inc. $ 52,500,000
9/20/2005 Icoria Inc. Clinical Data Inc. $ 12,500,000
9/21/2005 Valley Forge Scientific Synergetics $ 28,160,000
Xinhua Steris Medical System Co.,
9/22/2005 Ltd Steris Corporation $15,500,000
9/23/2005 Trestle Holdings Inc. Clarient Inc $ 3,000,000
9/26/2005 Sirona Dental Systems GmbH Schick Technologies Inc. $ 1,460,000,000
Innogenetics Diagnostica y Inverness Medical Innovations
9/29/2005 Terapeutica SA Inc. $ 18,656,720
Accurel Systems International
10/3/2005 Corporation Implant Sciences Corporation $ 11,300,000
10/12/2005 PET Scans of America Corporation Alliance Imaging Inc. $ 44,000,000
10/14/2005 MRP Group Inc. Escalon Medical Corporation $ 1,498,000
10/16/2005 Bio-logic Systems Corporation Natus Medical Inc. $ 66,000,000
Advanced Neuromodulation
10/16/2005 Systems St Jude Medical Inc. $ 1,300,000,000
10/17/2005 IntElect Medical Inc. Biomec Inc. $ 3,000,000
11/7/2005 HepaLife Technologies Inc. Fusion Capital Partners LLC $ 15,000,000
11/11/2005 Compex Technologies Inc. Encore Medical Corporation $ 111,000,000
11/14/2005 Inamed Corporation Allergan Inc. $ 3,200,000,000
11/21/2005 Specialized Health Products
Med-Design Corporation, The International, Inc. $ 5,029,000
12/1/2005 Savacor St Jude Medical Inc. $ 50,000,000
12/5/2005 Guidant Corporation Boston Scientific Corporation $ 27,000,000,000
12/5/2005 CUNO Inc. 3M Company $ 1,298,400,000
12/15/2005 New Med SAS DJ Orthopedics Inc. $ 15,600,000
12/16/2005 Animas Corporation Johnson & Johnson $ 518,000,000
12/19/2005 Spectral Diagnostics Inc.'s cardiac
immunoassay test business Nanogen Inc. $ 7,860,950
Del Global Technologies
12/27/2005 Villa Sistemi Medicali SpA Corporation $ 6,026,000
12/28/2005 Electa Lab Sri Clinical Data Inc. $ 1,800,000
12/31/2005 Innospine Kyphon Inc. $ 2,500,000
CLONDIAG chip technologies Inverness Medical Innovations
1/3/2006 GmbH Inc. $ 27,830,000
1/3/2006 Venetec International CR Bard Inc. $ 166,000,000
Guidant Corporation's vascular
intervention and endovascular
1/8/2006 businesses Abbott Laboratories Inc. $ 5,500,000,000
1/17/2006 Boston Scientific Corporation Abbott Laboratories Inc. $ 1,400,000,000
MedImpulse Ltd's treatment of American Medical Systems
1/18/2006 incontinence activity Holdings Inc. $ 50,000,000
1/23/2006 3F Therapeutics ATS Medical Inc. $ 57,360,000
2/1/2006 American Medical Instruments
Holdings Inc. Angiotech Pharmaceuticals Inc. $ 785,000,000
2/2/2006 Cutanogen Corp Cambriex BioScience $ 1,500,000
2/5/2006 AEG Elektrofotografie GmbH Hologic Inc. $ 26,000,000
2/13/2006 Curlin Medical Moog $ 75,000,000
Cyberkinetics Neurotechnology
2/15/2006 Andara Lifescience Systems Inc. $ 4,600,000
2/21/2006 Excel Technology Inc. Coherent Inc. $ 376,000,000
American Medical
2/21/2006 Spectrum Dental Inc. Technologies Inc. $ 1,070,000
2/24/2006 AzERx Inc.'s certain assets OrthoLogic Corporation $ 8,073,000
2/27/2006 Aircast Inc. DJ Orthopedics Inc. $ 290,000,000
2/27/2006 lonSpec Corporation Varian Medical Systems Inc. $ 16,000,000
Quintiles PharmaBio
2/28/2006 OrthoLogic Corporation Development $ 5,000,000
3/1/2006 PlasmaSol Corporation Stryker Corporation $ 17,500,000
3/5/2006 Riley Medical Inc. Symmetry Medical Inc. $ 45,000,000
3/9/2006 InnerCool Therapies Inc. Cardium Therapeutics Inc. $ 6,435,000
3/20/2006 Sightline Technologies Stryker Corporation $ 50,000,000
3/22/2006 Lifecor Inc. ZOLL Medical Corporation $ 10,300,000
3/27/2006 Mentor Coloplast AS $ 463,000,000
4/1/2006 MCTec BV Merit Medical Systems Inc. $ 3,000,000
4/12/2006 Syboron Dental Specialisties Danaher Corporation $ 2,000,000,000
4/17/2006 Suros Surgical Systems Hologic Inc. $ 240,000,000
Hypoguard Ltd; Hypoguard USA
4/18/2006 Inc Arkray Inc $ 45,140,830
4/18/2006 Western Medical Ltd Derma Sciences Inc. $ 6,500,000
Integra LifeSciences Holdings
4/20/2006 Miltex Instrument Company Inc. Corporation $ 101,000,000
4/24/2006 R2 Technologies Hologic Inc. $ 220,000,000
4/27/2006 Kimal plc's certain assets Arrow International Inc. $ 9,000,000
Siemens Medical Solutions
4/27/2006 Diagnostic Products Corporation USA Inc. $ 1,860,000,000
4/27/2006 Witt Biomedical Philips Medical Systems $ 165,000,000
4/30/2006 InnovaQuartz Inc. Laserscope $ 8,600,000
5/4/2006 Raven Biological Laboratories Inc. Mesa Laboratories Inc. $6,750,000
5/6/2006 BriteSmile Inc. Futuredontics Inc. $ 42,196,000
5/8/2006 Solarant Medical, Inc. (FKA: SURx, American Medical Systems
Inc.) Holdings Inc. $ 1,000,000
Integra LifeSciences Holdings
5/12/2006 Miltex Corporation $ 101,000,000
Mentor Corporation's male external
catheter assets; Coloplast A/S's male
5/18/2006 external catheter assets Rochester Medical Corporation $ 14,600,000
Inverness Medical Innovations
5/18/2006 TechLab Inc. Inc. $ 8,562,000
5/25/2006 Quill Medical Inc. Angiotech Pharmaceuticals Inc. $ 40,000,000
5/26/2006 IntraLuminal Therapeutics Inc. Kensey Nash Corporation $ 8,000,000
American Medical Systems
6/5/2006 Laserscope Holdings Inc. $ 715,000,000
6/8/2006 Arryx Haemonetics Corporation $ 26,000,000
6/15/2006 Intermagnetics General Philips Medical Systems $ 1,250,000,000
Island Dental Co Inc.; Darby
Medical Supply Co; Darby Dental
6/21/2006 Laboratory Supply Co Inc. Henry Schein Inc. $ 51,500,000
Integra LifeSciences Holdings
6/30/2006 Kinetikos Medical Inc. Corporation $ 40,000,000
ACON Laboratories Inc.'s Rapid Inverness Medical Innovations
7/2/2006 Diagnostics Business Inc. $ 175,000,000
7/3/2006 GENOME express SA Clinical Data Inc. $ 3,192,000
7/7/2006 Radiologix Inc. Primedex Health Systems Inc $ 221,000,000
7/8/2006 Blackstone Medical Inc. Orthofix International NV $ 333,000,000
7/13/2006 Ensure Medical Cordis/J&J $ 54,000,000
Confluent Surgical United States Surgical
7/18/2006 Corporation $ 255,000,000
7/21/2006 Epigenomics AG Affymetrix Inc. $ 2,007,060
7/31/2006 Carsen Assets Olympus America Inc. $ 27,834,230
100
8/2/2006 Gait Medical Corporation Theragenics Corporation $ 31,900,000
8/2/2006 Lifeline Biotech Solos Endoscopy $ 4,000,000
8/6/2006 ARRYX Inc. Haemonetics Corporation $ 26,000,000
8/8/2006 Materialise Dental NV DENTSPLY International Inc. $ 25,733,400
8/14/2006 TriPath Imaging Inc. Becton Dickinson & Company $ 350,000,000
8/24/2006 Odin Medical Technologies Ltd Medtronic Inc. $ 9,000,000
8/28/2006 Kerberos Proximal Solutions Fox Hollow Technologies Inc. $ 32,000,000
Everest Metal Finishing LLC;
8/31/2006 Everest Metal International Ltd Symmetry Medical Inc. $ 10,200,000
9/1/2006 Applied Imaging Corp. Genetix Group PLC $ 18,300,000
9/6/2006 Deltamed SA Natus Medical Inc. $ 3,977,930
9/10/2006 CNS Inc. GlaxoSmithKline plc $ 566,000,000
9/13/2006 Vision Systems Ltd Cytyc Corporation $ 449,775,110
9/27/2006 Scient'X SA Alphatec Holdings Inc. $ 56,500,000
9/27/2006 Ideal Medical Products SA Alphatec Holdings Inc. $ 70,136,000
9/27/2006 Fox Hollow Technologies Inc. Merck & Company Inc. $ 95,000,000
